http://www.pharmajournalist.com/pfizer-and-biontech-announce-positive-topline-results-from-pivotal-trial-of-covid-19-vaccine-in-children-5-to-11-years/ 2021-09-27T11:04:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/transcenta-received-ind-clearance-from-nmpa-of-its-anti-sclerostin-monoclonal-antibody-tst002/ 2021-09-27T11:10:54+00:00 https://pharmajournalist.com/wp-content/uploads/2021/09/Transcenta-Logo.jpg http://www.pharmajournalist.com/astrazeneca-and-oncoshot-establish-strategic-partnership-to-better-streamline-recruitment-process-for-cancer-clinical-trials/ 2021-09-27T11:12:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/phenomenex-announces-the-release-of-new-biozen-sec-size-exclusion-chromatography-columns/ 2021-09-27T11:14:16+00:00 https://pharmajournalist.com/wp-content/uploads/2021/09/phenomenex-office.jpg http://www.pharmajournalist.com/persephone-biosciences-inc-announces-collaboration-with-janssen-biotech-inc/ 2021-09-27T11:16:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/09/Persephone-Biosciences-Logo.png http://www.pharmajournalist.com/fda-approves-lexette-r-for-adolescent-plaque-psoriasis/ 2021-09-27T11:18:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-oxford-biotherapeutics-partnership-advances-second-oncology-drug-candidate-into-the-clinic/ 2021-09-27T11:19:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/hikma-and-faes-farma-enter-into-exclusive-licensing-agreement-for-the-commercialisation-of-bilastine-tablets-in-the-us/ 2021-09-27T11:21:18+00:00 https://pharmajournalist.com/wp-content/uploads/2020/01/hikma-logo.jpg http://www.pharmajournalist.com/perkinelmer-completes-acquisition-of-antibody-and-reagent-leader-biolegend/ 2021-09-27T11:22:54+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/perkinelmer.png http://www.pharmajournalist.com/exclusive-chair-interview-released-ahead-of-smis-medical-wearables-for-biosensors-virtual-conference-taking-place-in-4-weeks/ 2021-09-28T10:04:21+00:00 https://pharmajournalist.com/wp-content/uploads/2021/09/TP-001-Biosensors-1200x627-Andreas-Caduff-.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/09/TP-001-Biosensors-1200x627-Andreas-Caduff-.jpg http://www.pharmajournalist.com/verus-eventmagix-and-online-seminar-join-forces-to-offer-a-virtual-future-is-now-experience-to-partners-in-the-healthcare-industry/ 2021-10-07T21:42:47+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/future-is-now-event-online-seminar.png http://www.pharmajournalist.com/wp-content/uploads/2021/10/future-is-now-event-online-seminar.png http://www.pharmajournalist.com/boehringer-ingelheim-inaugurates-biopharmaceutical-production-facility-in-vienna-austria/ 2021-10-07T21:48:47+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/LSCC-quer-bearbeitet_klein.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/10/LSCC-quer-bearbeitet_klein.jpg http://www.pharmajournalist.com/moderna-to-build-state-of-the-art-mrna-facility-in-africa-to-manufacture-up-to-500-million-doses-per-year/ 2021-10-07T21:50:20+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/moderna-announces-european-medicines-agency-authorizes-third-dose-of-covid-19-vaccine-for-immunocompromised-individuals-aged-12-years-and-older/ 2021-10-07T21:51:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/voyager-therapeutics-announces-license-option-agreement-with-pfizer-for-next-generation-tracer-aav-capsids-to-enable-neurologic-and-cardiovascular-gene-therapy-programs/ 2021-10-07T21:53:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us/ 2021-10-07T21:55:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/viiv-healthcare-submits-fda-application-for-first-dispersible-single-tablet-regimen-containing-dolutegravir-dtg-for-children-living-with-hiv/ 2021-10-07T21:57:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/ViiV-Healthcare.png http://www.pharmajournalist.com/gsk-welcomes-who-recommendation-for-broad-roll-out-of-its-rtss-as01e-rtss-malaria-vaccine/ 2021-10-07T21:58:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/xencor-enters-global-collaboration-and-license-agreement-with-janssen-to-advance-plamotamab-and-xmab-cd28-bispecific-antibody-combinations-for-the-treatment-of-patients-with-b-cell-malignancies/ 2021-10-07T21:59:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ 2021-10-07T22:02:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/takeda-to-commercialize-next-generation-hunter-syndrome-therapy-through-collaboration-with-jcr-pharmaceuticals/ 2021-10-07T22:03:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/eqrx-and-absci-announce-partnership-to-discover-and-develop-next-generation-protein-based-drugs/ 2021-10-07T22:05:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/amerisourcebergen-supports-global-distribution-of-covid-19-vaccines/ 2021-10-07T22:07:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Amerisource.jpg http://www.pharmajournalist.com/xeris-pharmaceuticals-completes-acquisition-of-strongbridge-biopharma/ 2021-10-07T22:09:04+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/takeda-provides-update-on-tak-994-clinical-program/ 2021-10-07T22:10:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/atara-biotherapeutics-and-pierre-fabre-enter-strategic-collaboration-to-commercialize-tabelecleucel-tab-cel/ 2021-10-07T22:11:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Atara-Bio_logo.png http://www.pharmajournalist.com/stevanato-group-initiates-construction-on-new-u-s-facility/ 2021-10-07T22:13:48+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Stevanato_Group.jpg http://www.pharmajournalist.com/tonix-pharmaceuticals-announces-completion-of-acquisition-of-infectious-disease-rd-center-in-frederick-maryland/ 2021-10-07T22:15:06+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/tonix-pharmaceuticals.png http://www.pharmajournalist.com/acer-therapeutics-and-relief-therapeutics-announce-fda-acceptance-for-filing-of-new-drug-application-for-acer-001-to-treat-urea-cycle-disorders/ 2021-10-08T09:05:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-kites-tecartus-as-the-first-and-only-car-t-for-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ 2021-10-08T09:07:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/exclusive-chair-interview-released-ahead-of-smis-medical-wearables-for-biosensors-virtual-conference-in-2-weeks/ 2021-10-13T10:45:52+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/Medical-Wearables-for-Biosensors-USA.jpg http://www.pharmajournalist.com/registration-is-now-open-for-rna-therapeutics-2022/ 2021-10-13T11:12:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/RNA-Therapeutics-Conference-2021.jpg http://www.pharmajournalist.com/smis-4th-annual-ophthalmic-drugs-conference-chairmans-invitation-released/ 2021-10-15T10:09:12+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Opthalmic-Drug-Press-Release.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/10/Opthalmic-Drug-Press-Release.jpg http://www.pharmajournalist.com/conference-chair-di-morris-astrazeneca-invites-microbiologists-to-join-smis-10th-annual-pharmaceutical-microbiology-conference/ 2021-10-20T09:31:50+00:00 https://pharmajournalist.com/wp-content/uploads/2021/09/Pharmaceutical-Microbiology-UK-Banner.jpg http://www.pharmajournalist.com/registration-is-now-open-for-the-pre-filled-syringes-and-injectable-devices-conference-2022/ 2021-10-21T08:22:35+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Pre-Filled-Syringes_PR.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/10/Pre-Filled-Syringes_PR.jpg http://www.pharmajournalist.com/fsd-pharma-signs-agreement-with-covar-pharmaceuticals-to-support-the-development-of-lucid-psych/ 2021-10-21T08:45:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/cdisc-and-openclinica-collaborate-to-drive-academic-clinical-research-forward/ 2021-10-21T08:47:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/perkinelmer-and-honeycomb-biotechnologies-launch-the-hive-scrnaseq-solution-for-single-cell-analysis/ 2021-10-21T08:50:43+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/HIVE_kit_boxes_webready.jpg https://pharmajournalist.com/wp-content/uploads/2021/10/HIVE_kit_boxes_webready.jpg http://www.pharmajournalist.com/oncodesign-and-tiumbio-sign-collaboration-agreement-for-rd-of-fibrosis-drug-candidates/ 2021-10-22T09:27:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/mablink-bioscience-and-emergence-therapeutics-enter-into-a-licensing-agreement-to-develop-antibody-drug-conjugate-as-a-potential-cancer-therapy/ 2021-10-22T09:39:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/moderna-announces-fda-authorization-of-a-booster-dose-of-modernas-covid-19-vaccine-in-the-u-s/ 2021-10-22T09:41:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/biotage-acquires-atdbio-and-strengthens-its-position-in-dna-and-rna-oligonucleotide-synthesis-and-purification/ 2021-10-22T09:42:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/06/Biotage-Logo.jpg http://www.pharmajournalist.com/immusoft-and-takeda-collaborate-to-discover-and-develop-cell-therapies-for-rare-neurometabolic-disorders/ 2021-10-22T09:44:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/genecentric-therapeutics-collaborates-with-labcorp-to-develop-novel-rna-based-oncology-diagnostics/ 2021-10-22T09:45:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sutro-biopharma-and-bionova-pharmaceuticals-enter-into-collaboration-for-stro-001-in-greater-china/ 2021-10-22T09:47:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizer-and-biontech-announce-phase-3-trial-data-showing-high-efficacy-of-a-booster-dose-of-their-covid-19-vaccine/ 2021-10-22T09:49:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/johnson-johnson-covid-19-vaccine-booster-shot-unanimously-recommended-for-emergency-use-authorization-by-u-s-fda-advisory-committee/ 2021-10-22T09:51:10+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/amgen-successfully-completes-acquisition-of-teneobio-inc/ 2021-10-22T09:52:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/moleculin-receives-authorization-from-the-medicines-and-healthcare-products-regulatory-agency-mhra-to-commence-phase-1a-clinical-trial-of-wp1122-for-the-treatment-of-covid-19/ 2021-10-22T09:55:06+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Moleculin-Logo.jpg http://www.pharmajournalist.com/food-and-drug-administration-approves-expanded-indication-of-gileads-biktarvy-for-treatment-of-hiv-1-in-pediatric-populations/ 2021-10-22T09:56:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/silence-therapeutics-and-hansoh-pharma-announce-collaboration-to-develop-therapeutics-leveraging-silences-mrnai-gold-platform/ 2021-10-22T09:58:40+00:00 https://pharmajournalist.com/wp-content/uploads/2019/01/Silence-Therapeutics-Logo.png http://www.pharmajournalist.com/fda-approves-roches-tecentriq-as-adjuvant-treatment-for-certain-people-with-early-non-small-cell-lung-cancer/ 2021-10-22T10:00:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/curevac-to-shift-focus-of-covid-19-vaccine-development-to-second-generation-mrna-technology/ 2021-10-22T10:02:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/Curevac-logo.png http://www.pharmajournalist.com/pacira-biosciences-to-acquire-flexion-therapeutics-further-expanding-leadership-position-in-non-opioid-pain-management/ 2021-10-22T10:04:01+00:00 https://pharmajournalist.com/wp-content/uploads/2019/03/Pacira-Logo.png http://www.pharmajournalist.com/supernus-pharmaceuticals-to-acquire-adamas-pharmaceuticals-strengthening-its-cns-product-portfolio/ 2021-10-22T10:05:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/supernus-pharmaceuticals-inc-logo.jpg http://www.pharmajournalist.com/atreca-enters-into-licensing-agreement-with-bill-melinda-gates-medical-research-institute-to-develop-a-monoclonal-antibody-for-the-prevention-of-malaria/ 2021-10-22T10:07:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/beigene-and-nanolek-announce-approval-in-russia-for-brukinsa-zanubrutinib-for-treatment-of-patients-with-relapsed-or-refractory-mantle-cell-lymphoma/ 2021-10-22T10:09:53+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/exelixis-and-storm-therapeutics-enter-into-exclusive-collaboration-and-license-agreement-to-discover-and-develop-inhibitors-of-novel-rna-modifying-enzymes/ 2021-10-22T10:11:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Exelixis.jpg http://www.pharmajournalist.com/intellia-therapeutics-and-sparingvision-announce-strategic-collaboration-to-develop-novel-ocular-therapies-using-crispr-cas9-technology/ 2021-10-22T10:13:13+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/smi-group-launches-new-conference-the-transdermal-and-microneedle-delivery-conference/ 2021-10-25T11:08:48+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Transdermal-and-Microneedle-Delivery-Press-Release.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/10/Transdermal-and-Microneedle-Delivery-Press-Release.jpg http://www.pharmajournalist.com/ubiquigent-extends-and-expands-drug-discovery-collaboration-with-bristol-myers-squibb/ 2021-10-29T10:36:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/agomab-therapeutics-to-acquire-origo-biopharma/ 2021-10-29T10:38:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/xtalpi-and-signet-expand-ai-drug-discovery-collaboration-to-novel-cancer-target/ 2021-10-29T10:40:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/wuxi-biologics-completes-gmp-inspection-by-health-canada-for-drug-substance-facility/ 2021-10-29T10:41:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/wuxi-biologics-logo.png http://www.pharmajournalist.com/teva-and-modag-announce-licensing-collaboration-for-neurodegenerative-disease-drug-candidate/ 2021-10-29T10:43:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/boehringer-ingelheim-partners-with-thoeris-to-investigate-a-novel-approach-to-treat-urea-cycle-disorders/ 2021-10-29T10:44:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/xeris-pharmaceuticals-enters-collaboration-agreement-with-merck/ 2021-10-29T10:46:25+00:00 https://pharmajournalist.com/wp-content/uploads/2019/03/Xeris-Logo.jpg http://www.pharmajournalist.com/tremeau-expands-pipeline-with-novel-non-opioid-compound-for-the-treatment-of-acute-pain/ 2021-10-29T10:48:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/fda-approves-genentechs-susvimo-a-first-of-its-kind-therapeutic-approach-for-wet-age-related-macular-degeneration-amd/ 2021-10-29T10:50:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/tff-pharmaceuticals-receives-approval-from-health-canada-to-enter-human-clinical-trials-for-inhaled-formulation-of-niclosamide-to-treat-covid-19/ 2021-10-29T10:52:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/mpp-and-merck-enter-into-license-agreement-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-to-increase-broad-access-in-low-and-middle-income-countries/ 2021-10-29T10:54:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/sorrento-announces-encouraging-results-from-two-phase-2-studies-of-abivertinib-for-treatment-of-hospitalized-severe-covid-19-patients/ 2021-10-29T10:55:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/sorrento-therapeutics.jpg http://www.pharmajournalist.com/ptc-announces-expansion-of-translarna-label-to-include-ambulatory-patients-as-young-as-2-years-old-in-brazil/ 2021-10-29T10:58:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/PTC-Therapeutics.jpg http://www.pharmajournalist.com/bausch-lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-triamcinolone-acetonide-injectable-suspension-for-suprachoroidal-use-for-the-treatment-of-macular-edema-associated-with-uveitis/ 2021-10-29T11:00:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/inovio-announces-collaboration-with-colombia-memorandum-of-understanding-focuses-on-protecting-against-covid-19-and-supporting-broader-health-preparedness-initiatives/ 2021-10-29T11:16:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Inovio-pharma.jpg http://www.pharmajournalist.com/pfizer-and-biontech-to-provide-u-s-government-an-additional-50-million-pediatric-doses-of-covid-19-vaccine-to-support-further-preparedness-for-future-needs/ 2021-10-29T11:18:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/immunai-raises-215-million-to-accelerate-development-of-its-immune-first-drug-actuary-platform/ 2021-10-29T11:21:34+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Immunai-founders.jpg https://pharmajournalist.com/wp-content/uploads/2021/10/Immunai-founders.jpg http://www.pharmajournalist.com/takeda-to-acquire-gammadelta-therapeutics-to-accelerate-development-of-allogeneic-%ce%b3%ce%b4t-cell-therapies-addressing-solid-tumors/ 2021-10-29T11:23:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/vertex-and-mammoth-biosciences-announce-collaboration-to-develop-in-vivo-gene-editing-therapies-for-serious-diseases/ 2021-10-29T11:24:52+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cance/ 2021-10-29T11:26:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/smis-4th-annual-ophthalmic-drugs-conference-event-starts-in-less-than-3-weeks/ 2021-11-01T17:11:17+00:00 https://pharmajournalist.com/wp-content/uploads/2021/06/Ophthalmic.jpg http://www.pharmajournalist.com/green-circle-life-launches-covid-19-vaccination-mandate-compliance-solution/ 2021-11-05T13:02:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/drug-discovery.jpg http://www.pharmajournalist.com/acticor-biotech-announces-fda-acceptance-of-ind-application-for-glenzocimab-in-acute-ischemic-stroke/ 2021-11-05T13:03:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/moderna-and-metagenomi-establish-collaboration-to-develop-next-generation-in-vivo-gene-editing-therapeutics/ 2021-11-05T13:05:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/yokogawa-acquires-insilico-biotechnology-developer-of-innovative-bioprocess-digital-twin-technology/ 2021-11-05T13:06:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/venatorx-pharmaceuticals-announces-collaboration-with-roche-to-develop-new-class-of-antibiotics-targeting-who-critical-priority-pathogen/ 2021-11-05T13:07:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/wuxi-biologics-launches-a-new-gmp-commercial-drug-product-facility/ 2021-11-05T13:25:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/wuxi-biologics-logo.png http://www.pharmajournalist.com/fda-declines-emergency-use-authorization-for-zyesami-aviptadil-for-patients-with-critical-covid-19-with-respiratory-failure/ 2021-11-05T13:27:48+00:00 https://pharmajournalist.com/wp-content/uploads/2021/06/NRX-Pharma-Logo.jpeg http://www.pharmajournalist.com/dunad-therapeutics-enters-strategic-collaboration-with-novartis-to-develop-next-generation-oral-targeted-protein-degrader-therapies/ 2021-11-05T13:29:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/resverlogix-in-active-discussions-with-the-kingdom-of-moroccos-ministry-of-health-for-the-launch-of-covid-19-clinical-studies-with-first-in-class-drug-apabetalone/ 2021-11-05T13:31:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/Resverlogix-Logo.jpg http://www.pharmajournalist.com/novavax-files-for-provisional-approval-of-its-covid-19-vaccine-in-australia/ 2021-11-05T13:33:13+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/exclusive-interview-with-sriman-banerjee-head-of-packaging-development-cde-takeda/ 2021-11-12T10:41:29+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Pre-Filled-Syringes_Banner.jpg http://www.pharmajournalist.com/chmp-recommends-eu-approval-of-regeneron-antibody-cocktail-to-treat-and-prevent-covid-19/ 2021-11-12T11:09:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/national-institute-for-health-and-care-excellence-nice-issues-positive-guidance-for-kyowa-kirins-poteligeo-mogamulizumab-for-the-treatment-of-people-living-with-certain-ultra-rare-blood-c/ 2021-11-12T11:11:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/drug-discovery.jpg http://www.pharmajournalist.com/valneva-announces-european-commission-approval-of-advance-purchase-agreement-for-up-to-60-million-doses-of-inactivated-covid-19-vaccine-vla2001/ 2021-11-12T11:13:18+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/biohaven-and-pfizer-enter-strategic-collaboration-for-the-commercialization-of-rimegepant-outside-the-united-states/ 2021-11-12T11:14:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/eton-pharmaceuticals-and-azurity-pharmaceuticals-inc-announce-fda-approval-of-eprontia-topiramate-oral-solution/ 2021-11-12T11:16:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ocugen-announces-submission-of-emergency-use-authorization-request-to-the-us-fda-for-investigational-covid-19-vaccine-covaxin-bbv152-for-children-ages-2-18-years/ 2021-11-12T11:19:45+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/Ocugen_Logo.jpg http://www.pharmajournalist.com/chmp-recommends-eu-approval-of-ronapreve-to-treat-non-hospitalised-covid-19-patients-and-for-prophylaxis-of-the-disease/ 2021-11-12T11:21:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/fda-grants-profounda-orphan-drug-designation-approval-for-treatment-of-treatment-of-invasive-candidiasis-with-miltefosine/ 2021-11-12T11:23:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/azurity-pharmaceuticals-announces-fda-approval-of-eprontiatm-topiramate-oral-solution/ 2021-11-12T11:26:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/regenxbio-announces-closing-of-eye-care-collaboration-agreement-with-abbvie/ 2021-11-12T11:27:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/puretech-founded-entity-karuna-therapeutics-and-zai-lab-announce-strategic-collaboration-for-development-manufacturing-and-commercialization-of-karxt-in-greater-china/ 2021-11-12T11:29:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/omnicell-and-fresenius-kabi-collaborate-to-enhance-management-of-controlled-substances-in-u-s-hospitals/ 2021-11-12T11:32:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Fresenius-Kabi.jpg http://www.pharmajournalist.com/organon-to-acquire-forendo-pharma/ 2021-11-12T11:34:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-accepts-supplemental-new-drug-application-and-grants-priority-review-for-jardiance-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction/ 2021-11-12T11:36:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-university-of-chicago-extend-research-collaboration-to-support-preclinical-oncology-research-through-2025/ 2021-11-12T11:39:06+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/arbor-biotechnologies-closes-215-million-oversubscribed-series-b-financing-to-advance-next-generation-precision-editing-therapeutics/ 2021-11-12T11:41:44+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/merck-announces-receipt-of-antitrust-clearance-in-germany-and-austria-relating-to-tender-offer-to-acquire-acceleron-pharma-inc/ 2021-11-12T11:43:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/effrx-obtains-swiss-marketing-authorization-for-bronchitol-in-cystic-fibrosis/ 2021-11-12T11:46:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/microbiome-connect-gut-therapeutics-taking-place-in-new-amsterdam-location/ 2021-11-15T11:06:09+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/Pharma-Journalist-2-1.png http://www.pharmajournalist.com/wp-content/uploads/2021/11/Gut-Therapeutics.png http://www.pharmajournalist.com/qa-with-nestles-marcus-bohme/ 2021-11-18T13:31:14+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/Pharma-Journalist-2-1.png http://www.pharmajournalist.com/christophe-carite-svp-cmc-process-development-4d-pharma/ 2021-11-18T13:31:34+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/Pharma-Journalist-2-1.png http://www.pharmajournalist.com/key-speakers-and-presentations-released-for-the-13th-annual-rna-therapeutics-conference/ 2021-11-18T13:32:46+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/RNA-Therapeutics-Conference-2021.jpg http://www.pharmajournalist.com/pfizer-to-provide-u-s-government-with-10-million-treatment-courses-of-investigational-oral-antiviral-candidate-to-help-combat-covid-19/ 2021-11-19T08:45:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/gsk-and-vir-biotechnology-announce-united-states-government-agreements-to-purchase-sotrovimab-a-covid-19-treatment/ 2021-11-19T08:47:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/pfizer-completes-acquisition-of-trillium-therapeutics/ 2021-11-19T08:49:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/novavax-and-serum-institute-of-india-receive-emergency-use-authorization-for-covid-19-vaccine-in-the-philippines/ 2021-11-19T08:51:40+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/bioagilytix-secures-significant-new-investment-from-global-investor-cinven-to-fuel-continued-long-term-growth/ 2021-11-19T08:52:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/kala-pharmaceuticals-acquires-combangio/ 2021-11-19T08:54:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/twist-bioscience-launches-revelar-biotherapeutics-to-develop-and-commercialize-novel-covid-19-and-other-antibody-therapeutics-for-difficult-to-treat-diseases/ 2021-11-19T08:55:45+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Twist-Bioscience-logo.jpg http://www.pharmajournalist.com/novavax-announces-submission-of-biologics-license-application-in-south-korea-for-approval-of-nvx-cov2373/ 2021-11-19T08:57:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/johnson-johnson-announces-plans-to-accelerate-innovation-serve-patients-and-consumers-and-unlock-value-through-intent-to-separate-consumer-health-business/ 2021-11-19T08:58:54+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/eqrx-and-evotec-announce-integrated-drug-discovery-and-development-partnership/ 2021-11-19T09:00:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/novo-nordisk-to-acquire-dicerna-pharmaceuticals-including-the-rnai-research-technology-platform/ 2021-11-19T09:01:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/sotio-expands-its-antibody-drug-conjugate-pipeline-with-exclusive-collaboration-and-license-agreement-with-legochem-biosciences/ 2021-11-19T09:03:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/Sotio-Logo.jpg http://www.pharmajournalist.com/lonza-to-expand-microbial-development-laboratories/ 2021-11-19T09:04:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/lonza.jpg http://www.pharmajournalist.com/mimivax-llc-receives-fda-approval-to-initiate-a-new-phase-2b-clinical-study-for-the-treatment-of-newly-diagnosed-glioblastoma/ 2021-11-19T09:06:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/innocare-announces-the-clearance-of-clinical-trial-of-novel-shp2-allosteric-inhibitor-icp-189-by-u-s-fda/ 2021-11-19T09:08:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/acelyrin-closes-250-million-series-b-financing-and-announces-licensing-of-izokibep-a-late-stage-il-17a-inhibitor-to-treat-inflammatory-diseases/ 2021-11-19T09:09:57+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/health-canada-authorizes-booster-dose-of-modernas-covid-19-vaccine-in-individuals-18-years-of-age-and-older/ 2021-11-19T09:12:12+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/ronapreve-approved-by-european-commission-to-treat-non-hospitalised-covid-19-patients-and-for-prophylaxis-of-the-disease/ 2021-11-19T09:13:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/gilead-exercises-options-to-three-arcus-biosciences-clinical-stage-programs-and-adds-research-collaboration/ 2021-11-19T09:15:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/alcami-to-provide-analytical-support-services-for-novavax-covid-19-vaccine-candidate/ 2021-11-19T09:19:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Alcami-sales-office-japan.jpg http://www.pharmajournalist.com/arranta-bio-announces-completion-of-sale-of-florida-site-and-progress-on-150m-investment-plan-to-expand-development-and-commercial-manufacturing-services/ 2021-11-19T09:20:29+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/the-future-of-transdermal-and-microneedle-drug-delivery-according-to-ester-caffarel-salvador-associate-director-regenerative-medicine-leo-pharma-a-s/ 2021-11-25T08:46:00+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Transdermal-and-Microneedle-Delivery-Press-Release.jpg http://www.pharmajournalist.com/amgen-and-bushu-pharma-announce-expanded-supply-chain-partnership-across-japan-and-asia-pacific-region/ 2021-11-25T12:26:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/greenlight-biosciences-and-samsung-biologics-announce-collaboration-to-build-capacity-for-messenger-rna-vaccine-manufacturing/ 2021-11-25T12:28:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/valneva-signs-purchase-agreement-with-european-commission-for-its-inactivated-covid-19-vaccine-vla2001/ 2021-11-25T12:29:59+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/donaldson-company-acquires-solaris-biotechnology/ 2021-11-25T12:32:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/obseva-announces-u-s-fda-acceptance-of-new-drug-application-for-linzagolix/ 2021-11-25T12:33:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/navigating-the-challenges-and-legal-landscapes-of-parallel-trade/ 2021-11-25T13:34:01+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/P-372-PT-1200-x-627-.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/11/P-372-PT-1200-x-627-.jpg http://www.pharmajournalist.com/novavax-files-for-interim-authorization-of-covid-19-vaccine-in-singapore/ 2021-11-26T09:29:24+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/fda-approves-first-treatment-for-common-type-of-post-transplant-infection-that-is-resistant-to-other-drugs/ 2021-11-26T09:32:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/nykode-therapeutics-formerly-vaccibody-enters-into-multi-target-license-and-collaboration-agreement-with-regeneron/ 2021-11-26T09:34:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/vaccibody-becomes-nykode-therapeutics/ 2021-11-26T09:36:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/oncotelic-announces-positive-topline-data-for-ot-101-c001-covid-study/ 2021-11-26T09:38:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/twist-bioscience-enters-into-definitive-agreement-to-acquire-abveris-bolstering-biopharma-capabilities/ 2021-11-26T09:40:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/arrowhead-pharmaceuticals-enters-exclusive-license-agreement-with-gsk-for-aro-hsd/ 2021-11-26T09:41:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/arrowhead-pharma-logo.jpg http://www.pharmajournalist.com/cstone-pharmaceuticals-and-jiangsu-hengrui-pharmaceuticals-announce-strategic-partnership-and-exclusive-licensing-agreement-on-anti-ctla-4-monoclonal-antibody-cs1002-in-greater-china/ 2021-11-26T09:44:42+00:00 https://pharmajournalist.com/wp-content/uploads/2019/06/cstone-logo.jpg http://www.pharmajournalist.com/zenas-biopharma-acquires-exclusive-worldwide-rights-to-obexelimab-from-xencor/ 2021-11-26T09:45:57+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/Xencor_Logo.png http://www.pharmajournalist.com/vifor-pharma-to-spearhead-development-of-vascular-calcification-field-through-acquisition-of-sanifit-therapeutics-and-inositec-ag/ 2021-11-26T09:47:09+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/Vifor-Pharma-Logo.jpg http://www.pharmajournalist.com/trodelvy-sacituzumab-govitecan-granted-european-commission-marketing-authorization-for-treatment-of-metastatic-triple-negative-breast-cancer-in-second-line/ 2021-11-26T09:49:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/valneva-signs-purchase-agreement-with-european-commission-for-its-inactivated-covid-19-vaccine-vla2001-2/ 2021-11-26T09:52:24+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge/ 2021-11-26T09:53:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/regenxbio-announces-orphan-drug-designation-granted-to-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy/ 2021-11-26T09:57:04+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/REGENXBIO-logo.png http://www.pharmajournalist.com/neurocrine-biosciences-and-sosei-heptares-announce-collaboration-to-develop-novel-muscarinic-receptor-agonists-for-schizophrenia-and-other-neuropsychiatric-disorders/ 2021-11-26T09:58:34+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Neurocrine-Biosciences.jpg http://www.pharmajournalist.com/biontech-receives-fda-fast-track-designation-for-its-fixvac-candidate-bnt111-in-advanced-melanoma/ 2021-11-26T10:00:16+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/BioNTech.jpg http://www.pharmajournalist.com/7-key-takeaways-from-smis-10th-annual-pharmaceutical-microbiology-conference/ 2021-11-29T10:42:35+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/P-367-1200x627-EB100-.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/11/P-367-1200x627-EB100-.jpg http://www.pharmajournalist.com/only-6-weeks-to-go-until-the-pre-filled-syringes-and-injectable-devices-conference-2022/ 2021-12-02T10:35:54+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Pre-Filled-Syringes_Banner.jpg http://www.pharmajournalist.com/only-6-weeks-to-go-until-the-transdermal-and-microneedle-delivery-conference/ 2021-12-02T11:53:20+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Transdermal-and-Microneedle-Delivery-Press-Release.jpg http://www.pharmajournalist.com/indian-pharmaceutical-sector-gears-up-for-indias-largest-pharma-expo/ 2021-12-03T09:56:40+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/Pharma-Journalis-300X-250px.jpg http://www.pharmajournalist.com/mhra-grants-conditional-marketing-authorisation1-for-covid-19-treatment-xevudy-sotrovimab/ 2021-12-03T10:00:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/astellas-and-dyno-therapeutics-announce-research-collaboration-to-develop-next-generation-aav-gene-therapy-vectors-for-skeletal-and-cardiac-muscle/ 2021-12-03T10:02:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/premas-biotech-and-oravax-medical-to-test-their-triple-antigen-oral-vaccine-candidate-against-omicron-variant-of-concern/ 2021-12-03T10:06:28+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/Premas-Biotech.jpg http://www.pharmajournalist.com/aws-helps-pfizer-accelerate-drug-development-and-clinical-manufacturing/ 2021-12-03T10:08:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/first-wave-biopharma-announces-independent-data-monitoring-committee-provides-positive-interim-safety-assessment-for-part-2-covid-19-reservoir-clinical-trial-of-niclosamide-for-the-treatment-of-gastro/ 2021-12-03T10:09:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children/ 2021-12-03T10:12:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/merck-group.jpg http://www.pharmajournalist.com/fda-actively-working-to-investigate-address-potential-impacts-of-omicron-variant-urges-vaccination-and-boosters/ 2021-12-03T10:13:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/bone-therapeutics-and-link-health-sign-a-non-binding-term-sheet-for-the-global-rights-of-allob/ 2021-12-03T10:39:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/enzychem-to-partner-with-zydus-cadila-to-manufacture-covid-19-plasmid-dna-vaccine-in-korea/ 2021-12-03T10:41:08+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/a-powerful-investment-alliance-of-aztiq-and-innobic-acquires-alvogens-shares-in-lotus-and-adalvo-in-a-us475m-deal/ 2021-12-03T10:42:54+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/resilience-acquires-swiftscale-biologics-a-leader-in-cell-free-protein-synthesis-technology/ 2021-12-03T10:44:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/nj-bio-expands-its-state-of-the-art-facility-in-princeton-new-jersey/ 2021-12-03T10:46:11+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/NJBio_Facility_Princeton_NJ.jpg https://pharmajournalist.com/wp-content/uploads/2021/12/NJBio_Facility_Princeton_NJ.jpg http://www.pharmajournalist.com/sanofi-to-acquire-origimm-biotechnology-in-first-move-to-treat-acne-with-vaccine-based-immunotherapy/ 2021-12-03T10:47:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/sanofi.jpg http://www.pharmajournalist.com/chiesi-and-ucb-enter-global-license-agreement-for-zampilimab-a-novel-monoclonal-antibody-for-fibrotic-lung-diseases/ 2021-12-03T10:49:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-ind-for-irakimid-degrader-kt-413/ 2021-12-03T11:06:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/blueprint-medicines-to-expand-precision-therapy-leadership-in-lung-cancer-with-acquisition-of-lengo-therapeutics/ 2021-12-03T11:08:08+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-confirms-detection-of-sars-cov-2-in-samples-containing-the-omicron-variant-with-its-taqpath-covid-19-tests/ 2021-12-03T11:10:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/valneva-confirms-initiation-of-rolling-review-with-ema-and-provides-updates-on-its-covid-19-vaccine-program-vla2001/ 2021-12-03T11:11:41+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/valneva-and-idt-biologika-announce-collaboration-for-production-of-inactivated-covid-19-vaccine-vla2001/ 2021-12-03T11:13:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/lynparza-granted-priority-review-in-the-us-for-brca-mutated-her2-negative-high-risk-early-breast-cancer/ 2021-12-03T11:15:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/abbvie-submits-application-for-risankizumab-skyrizi-in-moderate-to-severe-crohns-disease-to-ema/ 2021-12-03T11:16:34+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/avacta-announces-fda-approval-of-its-investigational-new-drug-ind-application-for-ava6000/ 2021-12-03T11:18:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/quell-therapeutics-raises-156-million-in-oversubscribed-series-b-financing-to-advance-its-pioneering-multi-modular-engineered-t-regulatory-treg-cell-therapy-pipeline-and-platform/ 2021-12-03T11:19:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/smi-launches-its-9th-annual-pre-filled-syringes-east-coast-conference/ 2021-12-06T11:58:23+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-373-PFS-EC-1200-x-627-.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/12/P-373-PFS-EC-1200-x-627-.jpg http://www.pharmajournalist.com/smis-3d-cell-culture-conference-2022-speakers-announced/ 2021-12-10T00:15:03+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-368-3D-Cell-Culture-2022-1200x627-1.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/12/P-368-3D-Cell-Culture-2022-1200x627-1.jpg http://www.pharmajournalist.com/co-chairs-philip-hewitt-and-stefan-pryzyborski-invitation-to-join-smis-5th-annual-3d-cell-culture-conference/ 2021-12-10T00:18:42+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-368-3D-Cell-Culture-2022-1200x627-1.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/12/P-368-3D-Cell-Culture-2022-1200x627-1.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-completes-acquisition-of-ppd/ 2021-12-10T01:16:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/brii-bio-announces-amubarvimab-romlusevimab-combination-received-approval-from-nmpa-as-first-covid-19-neutralizing-antibody-combination-therapy-in-china/ 2021-12-10T01:20:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/evusheld-formerly-azd7442-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19/ 2021-12-10T01:22:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/alvotech-and-oaktree-acquisition-corp-ii-announce-merger-agreement-to-create-a-leading-publicly-traded-global-biopharmaceutical-company/ 2021-12-10T01:24:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/astrazeneca-and-ionis-sign-deal-to-develop-and-commercialise-eplontersen/ 2021-12-10T01:25:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/cp-cov03-a-niclosamide-based-oral-antiviral-drug-under-study-as-possible-cure-for-covid-19-variants/ 2021-12-10T01:30:24+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/Hyundai-Bioscience.jpg https://pharmajournalist.com/wp-content/uploads/2021/12/Hyundai-Bioscience.jpg http://www.pharmajournalist.com/gritstone-bio-and-cepi-expand-vaccine-agreement-to-tackle-omicron-variant/ 2021-12-10T01:33:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/neurop-receives-fda-orphan-drug-designation-for-np10679-for-treatment-of-subarachnoid-hemorrhage/ 2021-12-10T01:35:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/genscript-probio-opens-chinas-largest-commercial-gmp-plasmid-manufacturing-facility/ 2021-12-10T01:40:05+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/GenScript-ProBio.jpg https://pharmajournalist.com/wp-content/uploads/2021/12/GenScript-ProBio.jpg http://www.pharmajournalist.com/pacbio-and-ucla-health-announce-research-collaboration-for-whole-genome-sequencing-in-rare-diseases/ 2021-12-10T01:41:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/telix-and-nucliber-sign-distribution-agreement-for-prostate-cancer-imaging-in-spain/ 2021-12-10T01:43:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/recursion-and-bayer-expand-fibrosis-collaboration-to-include-inferential-search-capabilities/ 2021-12-10T01:44:21+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/Recursion-Logo.jpg http://www.pharmajournalist.com/jacobio-receives-ind-approval-for-combination-therapy-of-kras-g12c-and-cetuximab-injection-in-china/ 2021-12-10T01:45:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/prestige-biopharma-and-dr-reddys-announce-partnership-to-commercialize-trastuzumab-biosimilar-in-select-countries-in-latin-america-and-southeast-asia/ 2021-12-10T01:47:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/dr-reddy-logo.png http://www.pharmajournalist.com/arbutus-biopharma-x-chem-and-proteros-biostructures-achieve-first-milestone-under-covid-19-discovery-research-and-license-agreement/ 2021-12-10T01:49:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/merck-announces-pause-in-enrollment-for-two-phase-3-clinical-trials-of-investigational-once-monthly-oral-islatravir-for-pre-exposure-prophylaxis-prep-of-hiv-1-infection/ 2021-12-10T08:36:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/ema-accepts-regulatory-submission-for-olipudase-alfa-the-first-potential-therapy-for-asmd/ 2021-12-10T08:38:36+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/quantum-genomics-signs-an-exclusive-license-and-production-agreement-with-gulf-pharmaceuticals-industries-julphar/ 2021-12-10T08:40:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resection/ 2021-12-10T08:43:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/syndax-pharmaceuticals-announces-closing-of-global-collaboration-and-license-agreement-for-axatilimab/ 2021-12-10T08:48:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/rapid-dose-therapeutics-signs-product-supply-agreement-with-oakland-health-limited-in-the-united-kingdom/ 2021-12-10T08:49:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/exclusive-speaker-interview-with-martin-akerman-envisagenics-released-ahead-of-the-rna-therapeutics-conference-2022/ 2021-12-14T00:46:05+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-370-2022-650x650-.jpg https://pharmajournalist.com/wp-content/uploads/2021/12/P-370-2022-650x650-.jpg http://www.pharmajournalist.com/book-to-attend-the-parallel-trade-conference-before-midnight-friday-17th-december-and-save-200/ 2021-12-16T00:45:40+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/Parallel-Trade-Pharma-Journalist.jpg http://www.pharmajournalist.com/biogen-and-therapanacea-announce-new-collaboration-with-the-potential-to-advance-digital-health-for-personalized-medicine-in-neuroscience/ 2021-12-16T00:53:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/merck-collaborates-with-innovative-biotech-to-support-establishment-of-first-vaccine-production-facility-in-nigeria/ 2021-12-16T00:54:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/pfizer-to-acquire-arena-pharmaceuticals/ 2021-12-16T00:56:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/samsung-biologics-and-astrazeneca-expand-strategic-manufacturing-partnership-to-include-covid-19-and-cancer-therapy/ 2021-12-16T00:58:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/take-the-state-of-the-industry-survey-and-add-your-views-to-the-hundreds-we-already-have-from-across-the-industry/ 2021-12-17T13:03:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/ema-issues-advice-for-potential-early-use-of-pfizers-novel-covid-19-oral-antiviral-candidate/ 2021-12-17T13:38:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/sab-biotherapeutics-announces-sab-185-retains-neutralization-against-omicron-sars-cov-2-variant-in-vitro/ 2021-12-17T13:40:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/SAB-Biotherapeutics-Logo.jpg http://www.pharmajournalist.com/european-commission-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-individuals-18-years-of-age-and-older/ 2021-12-17T13:42:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/pfizer-announces-additional-phase-2-3-study-results-confirming-robust-efficacy-of-novel-covid-19-oral-antiviral-treatment-candidate-in-reducing-risk-of-hospitalization-or-death/ 2021-12-17T13:44:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/atea-pharmaceuticals-introduces-new-strategic-clinical-development-program-for-at-527-in-covid-19/ 2021-12-17T13:45:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/lilly-and-foghorn-announce-strategic-collaboration-for-novel-oncology-targets-using-foghorns-proprietary-gene-traffic-control-platform/ 2021-12-17T13:47:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lilly-and-regor-therapeutics-group-enter-into-strategic-collaboration-to-discover-and-develop-novel-therapies-for-metabolic-disorders/ 2021-12-17T14:57:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/antengene-announces-clinical-collaboration-with-bristol-myers-squibb-to-evaluate-atg-017-in-combination-with-opdivonivolumab-in-advanced-solid-tumors/ 2021-12-17T14:59:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/biomarin-and-skyline-therapeutics-announce-strategic-collaboration-to-develop-novel-gene-therapies-for-cardiovascular-diseases/ 2021-12-17T15:00:52+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Biomarin-Pharma-Logo.jpg http://www.pharmajournalist.com/navidea-biopharmaceuticals-announces-launch-of-phase-3-clinical-trial-in-rheumatoid-arthritis/ 2021-12-17T15:02:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/alpine-immune-sciences-and-horizon-therapeutics-plc-announce-exclusive-license-and-collaboration-agreement-to-develop-novel-protein-based-therapies-for-autoimmune-and-inflammatory-diseases/ 2021-12-17T15:04:09+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/Horizon-Therapeutics-Logo.jpg http://www.pharmajournalist.com/fda-grants-priority-review-for-spesolimab-for-the-treatment-of-flares-in-patients-with-generalized-pustular-psoriasis-gpp-a-rare-life-threatening-skin-disease/ 2021-12-17T15:05:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/agex-therapeutics-to-collaborate-with-university-of-california-irvine-on-research-program-for-exosome-based-therapies-for-certain-brain-disorders/ 2021-12-17T15:07:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/AGEX_Logo.jpg http://www.pharmajournalist.com/zealand-pharma-announces-seven-year-200-million-financing-agreement-with-oberland-capital/ 2021-12-17T15:09:28+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/immatics-and-bristol-myers-squibb-enter-into-global-exclusive-license-for-immatics-tcr-bispecific-program-ima401/ 2021-12-17T15:14:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/novo-nordisk-invests-more-than-dkk-17-bn-in-expansion-of-the-manufacturing-facilities-in-kalundborg-denmark/ 2021-12-17T15:16:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/european-commission-approves-pfizers-cibinqo-abrocitinib-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis/ 2021-12-17T15:17:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/rakuten-medical-announces-fda-acceptance-of-an-investigational-new-drug-ind-application-for-rm-1995-a-conjugate-of-ir700-and-anti-cd25-antibody/ 2021-12-17T15:20:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/evotec-receives-us-18-m-grant-for-womens-health/ 2021-12-17T15:22:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/valneva-announces-positive-homologous-booster-data-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/ 2021-12-17T15:38:41+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/the-pre-filled-syringes-and-injectable-devices-conference-2022-is-now-a-virtual-event-online-access-only/ 2021-12-20T14:00:22+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Pre-Filled-Syringes-Virtual.jpg http://www.pharmajournalist.com/smis-10th-annual-pharmaceutical-microbiology-uk-conference-a-virtual-conference-with-online-access-only/ 2021-12-20T14:21:38+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-367-Pharma-Microbiology-UK-2022-1200x627-Virtual.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/12/P-367-Pharma-Microbiology-UK-2022-1200x627-Virtual.jpg http://www.pharmajournalist.com/the-transdermal-and-microneedle-drug-delivery-conference-2022-is-now-a-virtual-event-online-access-only/ 2021-12-20T15:04:39+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Transdermal-and-Microneedle-Delivery-Press-Release.jpg http://www.pharmajournalist.com/exploring-the-impact-of-machine-learning-and-artificial-intelligence-in-drug-development-from-discovery-to-healthcare/ 2021-12-20T17:29:59+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-371-AI-in-Drug-Discovery-1200x627-banner.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/12/P-371-AI-in-Drug-Discovery-1200x627-banner.jpg http://www.pharmajournalist.com/advancing-ai-drug-discovery-in-clinical-trials-at-smis-3rd-annual-ai-in-drug-discovery-conference/ 2021-12-20T17:36:37+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-371-AI-in-Drug-Discovery-1200x627-banner.jpg http://www.pharmajournalist.com/wp-content/uploads/2021/12/P-371-AI-in-Drug-Discovery-1200x627-banner.jpg http://www.pharmajournalist.com/purify22-all-set-to-usher-in-a-vibrant-2022/ 2022-01-04T17:47:50+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/PURIFY22-Pharma-Journalist.gif http://www.pharmajournalist.com/wp-content/uploads/2022/01/image006.png http://www.pharmajournalist.com/exclusive-speaker-interview-with-nagy-habib-imperial-college-london-mina-therapeutics-released-ahead-of-the-rna-therapeutics-conference-2022/ 2022-01-05T17:18:34+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-370-2022-650x650-1.jpg http://www.pharmajournalist.com/interim-results-of-the-pre-filled-syringes-and-injectable-drug-devices-survey-2021-2022/ 2022-01-06T17:38:47+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Pre-Filled-Syringes-Online-Conference.jpg http://www.pharmajournalist.com/the-transdermal-and-microneedle-drug-delivery-virtual-conference-2022-is-now-only-3-weeks-away/ 2022-01-06T17:49:37+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Transdermal-and-Microneedle-Delivery-Press-Release.jpg http://www.pharmajournalist.com/pfizer-and-biontech-sign-new-global-collaboration-agreement-to-develop-first-mrna-based-shingles-vaccine/ 2022-01-07T09:04:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/nrx-pharmaceuticals-submits-emergency-use-authorization-application-to-fda-for-zyesami/ 2022-01-07T09:07:13+00:00 https://pharmajournalist.com/wp-content/uploads/2021/06/NRX-Pharma-Logo.jpeg http://www.pharmajournalist.com/real-world-evidence-shows-johnson-johnson-covid-19-vaccine-demonstrates-durable-protection-against-breakthrough-infection-hospitalization-and-intensive-care-unit-admission-in-the-united-states/ 2022-01-07T09:08:51+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso-for-sma/ 2022-01-07T09:10:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/genprex-receives-fda-fast-track-designation-for-reqorsa-immunogene-therapy-in-combination-with-keytruda-for-the-treatment-of-non-small-cell-lung-cancer/ 2022-01-07T09:13:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/pfizer-and-biontech-receive-fda-emergency-use-authorization-of-covid-19-vaccine-booster-for-individuals-12-years-of-age-and-older/ 2022-01-07T09:15:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/novavax-submits-final-data-packages-to-u-s-fda-as-prerequisite-to-emergency-use-authorization-application-request-for-covid-19-vaccine/ 2022-01-07T09:17:48+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/wuxi-biologics-and-immuneoncia-sign-mou-for-development-and-manufacturing-of-anti-pd-l1-cd47-bispecific-antibody/ 2022-01-07T09:19:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/investigational-alzheimers-disease-therapy-lecanemab-granted-fda-fast-track-designation/ 2022-01-07T09:21:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/merck-and-ridgebacks-molnupiravir-receives-u-s-fda-emergency-use-authorization-for-the-treatment-of-high-risk-adults-with-mild-to-moderate-covid-19/ 2022-01-07T09:24:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/trexbio-announces-collaboration-with-janssen-to-discover-novel-targets-for-immunology-and-inflammation/ 2022-01-07T09:26:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/amgen-and-generate-biomedicines-announce-multi-target-multi-modality-research-collaboration-agreement/ 2022-01-07T09:28:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/sri-international-announces-collaboration-agreement-with-janssen/ 2022-01-07T09:31:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/genprex-expands-gene-therapy-oncology-pipeline-to-include-small-cell-lung-cancer/ 2022-01-07T09:34:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/verseau-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-vtx-0811-a-psgl-1-monoclonal-antibody/ 2022-01-07T09:36:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ascletis-expands-ritonavir-oral-tablet-production-and-announces-oral-direct-acting-antiviral-pipeline-against-sars-cov-2-virus/ 2022-01-07T09:38:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/ascletis-logo.jpg http://www.pharmajournalist.com/amphastar-receives-fda-tentative-approval-for-vasopressin/ 2022-01-07T09:40:23+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/Amphastar.jpg http://www.pharmajournalist.com/ionis-and-astrazeneca-close-deal-to-develop-and-commercialize-eplontersen/ 2022-01-07T09:42:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/ionis-pharma1.jpg http://www.pharmajournalist.com/novo-nordisk-announces-completion-of-dicerna-pharmaceuticals-acquisition/ 2022-01-07T09:45:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/amador-bioscience-completed-the-acquisition-of-ann-arbor-pharmacometrics-group-a2pg/ 2022-01-07T09:47:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sedana-medical-receives-ind-approval-for-us-trial/ 2022-01-07T09:49:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/novavax-and-sk-bioscience-expand-manufacturing-agreement/ 2022-01-07T09:51:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/karyopharm-and-menarini-group-enter-into-exclusive-license-agreement-to-commercialize-nexpovio-selinexor-in-europe-and-other-key-global-territories/ 2022-01-07T09:53:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/karyopharma-logo.png http://www.pharmajournalist.com/exclusive-speaker-interview-with-karen-capper-astrazeneca-ahead-of-the-pharmaceutical-microbiology-uk-virtual-conference/ 2022-01-07T09:58:02+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-367-Pharma-Microbiology-UK-2022-1200x627-Virtual-1.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/01/P-367-Pharma-Microbiology-UK-2022-1200x627-Virtual-1.jpg http://www.pharmajournalist.com/bighat-biosciences-completes-first-stage-of-research-collaboration-with-amgen/ 2022-01-14T11:16:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/neutron-therapeutics-and-cosylab-announce-strategic-collaboration-to-bring-boron-neutron-capture-therapy-to-patients/ 2022-01-14T11:23:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/century-therapeutics-and-bristol-myers-squibb-enter-into-a-strategic-collaboration-to-develop-ipsc-derived-allogeneic-cell-therapies/ 2022-01-14T11:26:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/pfizer-enters-into-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-delivery-system-for-use-in-mrna-vaccines-and-therapeutics/ 2022-01-14T11:28:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/bayer-and-mammoth-biosciences-to-collaborate-on-novel-gene-editing-technology/ 2022-01-14T11:29:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/novartis-and-molecular-partners-report-positive-topline-data-from-phase-2-study-for-ensovibep-mp0420-a-darpin-antiviral-therapeutic-for-covid-19/ 2022-01-14T11:31:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/benevolentai-announces-3-year-collaboration-expansion-with-astrazeneca-focused-on-systemic-lupus-erythematosus-and-heart-failure/ 2022-01-14T11:41:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/benevolentAI.jpg http://www.pharmajournalist.com/european-commission-approves-kaftrio-ivacaftor-tezacaftor-elexacaftor-in-combination-with-ivacaftor-to-treat-children-with-cystic-fibrosis-ages-6-to-11-years/ 2022-01-14T18:09:23+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/abl-bio-enters-global-collaboration-and-license-agreement-with-sanofi-to-advance-abl301-for-the-treatment-of-parkinsons-disease/ 2022-01-14T18:13:51+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab-authorised-for-the-early-treatment-of-covid-19/ 2022-01-14T18:16:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/adamis-pharmaceuticals-submits-fast-track-application-to-fda-for-tempol-for-the-treatment-and-prevention-of-covid-19/ 2022-01-14T18:19:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/new-speakers-from-abbvie-gsk-scripps-research-and-engitix-therapeutics-join-3d-cell-culture-virtual-conference-in-4-weeks/ 2022-01-17T06:45:56+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-368-2022-1200x627-4WKSBanner-VAO-.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/01/P-368-2022-1200x627-4WKSBanner-VAO-.jpg http://www.pharmajournalist.com/ucb-to-acquire-zogenix/ 2022-01-20T22:32:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/evotec-and-lilly-enter-into-drug-discovery-collaboration-in-metabolic-diseases/ 2022-01-20T22:33:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/book-to-attend-the-parallel-trade-conference-before-midnight-friday-28-th-january-and-save-100/ 2022-01-24T07:07:41+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/Parallel-Trade-Pharma-Journalist.jpg http://www.pharmajournalist.com/green-valley-obtains-ind-approval-from-u-s-fda-for-sodium-oligomannates-global-phase-ii-clinical-trial-in-treating-parkinsons-disease/ 2022-01-24T07:52:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kinnate-biopharma-announces-fda-clearance-of-investigational-drug-application-for-kin-3248/ 2022-01-24T07:55:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/boehringer-ingelheim-announces-collaboration-with-mabgenesis-to-discover-and-develop-novel-monoclonal-antibodies-in-canine/ 2022-01-24T07:58:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/seegene-to-launch-new-covid-19-pcr-test-with-a-reduced-turnaround-time-optimized-for-mass-testing/ 2022-01-24T08:02:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/senhwas-silmitasertib-receives-us-fda-orphan-drug-designation-for-the-treatment-of-biliary-tract-cancer/ 2022-01-24T08:05:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/%e2%80%8bsyapse-extends-collaboration-with-pfizer-to-continue-to-generate-real-world-evidence-in-breast-cancer/ 2022-01-24T08:08:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/bluerock-therapeutics-announces-first-patient-dosed-in-canada-in-phase-1-trial-in-patients-with-advanced-parkinsons-disease/ 2022-01-24T08:10:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/mustgrow-and-bayer-sign-exclusive-agreement-to-develop-sustainable-organic-biologicals-in-europe-asia-pacific-middle-east-and-africa/ 2022-01-24T08:15:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/fda-approves-veklury-remdesivir-for-the-treatment-of-non-hospitalized-patients-at-high-risk-for-covid-19-disease-progression/ 2022-01-24T08:18:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/bristol-myers-squibb-receives-approval-for-abecma-idecabtagene-vicleucel-the-first-car-t-therapy-approved-for-the-treatment-of-multiple-myeloma-in-japan/ 2022-01-24T08:20:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/nuvation-bio-announces-fda-clearance-of-investigational-new-drug-application-for-nuv-868-for-the-treatment-of-advanced-solid-tumors/ 2022-01-24T08:23:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/pfizer-shares-in-vitro-efficacy-of-novel-covid-19-oral-treatment-against-omicron-variant/ 2022-01-24T08:25:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/tony-wood-appointed-chief-scientific-officer-designate-gsk/ 2022-01-24T08:28:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/merck-and-ridgeback-announce-supply-agreement-with-unicef-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine/ 2022-01-24T08:31:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/abbisko-therapeutics-announces-worldwide-collaboration-with-lilly-to-discover-and-develop-novel-molecules/ 2022-01-24T08:36:21+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-second-indication-for-skyrizi-risankizumab-rzaa-to-treat-adults-with-active-psoriatic-arthritis/ 2022-01-24T08:42:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-accepts-for-review-libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-for-first-line-treatment-of-advanced-nsclc/ 2022-01-24T08:44:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ono-expands-drug-discovery-collaboration-with-neurimmune-ag-in-the-field-of-neurodegenerative-diseases/ 2022-01-24T08:47:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/colorcon-ventures-invests-in-intelligent-pharma-manufacturing-system-provider-apprentice-io/ 2022-01-24T09:09:43+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/Colorcon-Ventures-Logo.jpg http://www.pharmajournalist.com/xcellbio-announces-27-5-million-series-b-financing/ 2022-01-24T09:13:14+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/selexis-and-inotrem-enter-service-agreement-to-advance-inotrems-chronic-inflammatory-disease-program/ 2022-01-24T09:15:38+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/Selexis-Cell-Line-Development.jpg http://www.pharmajournalist.com/lonza-drug-product-services-participates-in-the-realhope-project-to-assess-and-improve-protein-stability/ 2022-01-24T09:17:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/lonza.jpg http://www.pharmajournalist.com/darren-green-gsk-conference-chair-invitation-to-attend-3rd-annual-ai-in-drug-discovery-conference/ 2022-01-24T09:22:35+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-371-Darren-Green-Chair-.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/01/P-371-Darren-Green-Chair-.jpg http://www.pharmajournalist.com/registration-is-now-open-for-highly-potent-active-pharmaceutical-ingredients-2022/ 2022-01-25T08:50:02+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-376-HPAPI2022-650x650-.jpg https://pharmajournalist.com/wp-content/uploads/2022/01/P-376-HPAPI2022-650x650-.jpg http://www.pharmajournalist.com/book-before-31st-january-2022-and-save-200-on-entry-to-the-pre-filled-syringes-east-coast-conference/ 2022-01-26T09:05:50+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-373-PFS-EC-300-x-200-copy.jpg http://www.pharmajournalist.com/reuters-digital-health-forum-to-bring-together-global-leaders-on-the-transformative-potential-of-technology-in-healthcare/ 2022-01-26T09:14:17+00:00 http://www.pharmajournalist.com/two-weeks-to-go-until-the-rna-therapeutics-conference-takes-place/ 2022-01-27T08:37:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/RNA-Therapeutics-Pharma-Journalist.jpg http://www.pharmajournalist.com/purify22-to-address-challenges-opportunities-and-full-scale-application-of-chromatography-to-future-manufacturing-opines-s-k-jana-director-rd-and-manufacturing-serum-institute/ 2022-01-27T08:51:12+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/PURIFY22-Pharma-Journalist.gif http://www.pharmajournalist.com/wp-content/uploads/2022/01/image006.png http://www.pharmajournalist.com/cocrystal-pharma-selects-two-lead-antiviral-drug-candidates-for-its-covid-19-oral-drug-program/ 2022-01-28T09:34:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/ec-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-surgery/ 2022-01-28T09:36:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/crowell-moring-unveils-crowell-health-solutions/ 2022-01-28T09:41:16+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/Crowell-Health-Solutions.png http://www.pharmajournalist.com/metagenomi-closes-oversubscribed-175m-series-b-financing-to-advance-therapeutic-pipeline-and-expand-novel-gene-editing-platform/ 2022-01-28T09:44:59+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/merck-provides-u-s-and-japan-regulatory-update-for-gefapixant/ 2022-01-28T09:47:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/fda-limits-use-of-certain-monoclonal-antibodies-to-treat-covid-19-due-to-the-omicron-variant/ 2022-01-28T09:49:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/pfizer-and-opko-provide-update-on-the-biologics-license-application-for-somatrogon-for-pediatric-growth-hormone-deficiency/ 2022-01-28T09:52:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/haemalogix-and-lonza-collaborate-to-manufacture-kappamab-a-multiple-myeloma-drug-candidate/ 2022-01-28T09:54:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/Lonza.jpg http://www.pharmajournalist.com/pfizer-receives-chmp-positive-opinion-for-novel-covid-19-oral-treatment/ 2022-01-28T09:56:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/atara-biotherapeutics-enters-strategic-manufacturing-partnership-with-fujifilm/ 2022-01-28T10:22:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Atara-Bio_logo.png http://www.pharmajournalist.com/polydex-pharmaceuticals-announces-collaboration-with-termanox-water-treatment-solutions-for-novel-use-of-native-dextran/ 2022-01-28T10:24:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/agilent-announces-the-innovative-seahorse-xf-pro-analyzer/ 2022-01-28T10:31:13+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/agilent-logo.png http://www.pharmajournalist.com/prospection-and-novotech-partner-to-accelerate-clinical-trials-with-real-world-evidence/ 2022-01-28T10:33:19+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ocugen-signs-letter-of-intent-to-acquire-vaccine-manufacturing-rd-hub-in-ontario-canada/ 2022-01-28T10:38:04+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/Ocugen_Logo.jpg http://www.pharmajournalist.com/roches-evrysdi-risdiplam-granted-fda-priority-review-for-treatment-of-pre-symptomatic-babies-under-2-months-of-age-with-spinal-muscular-atrophy-sma/ 2022-01-28T10:39:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/twist-bioscience-signs-collaboration-with-artisan-bio-to-engineer-next-generation-cell-therapeutics/ 2022-01-28T10:41:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/amyris-to-acquire-menolabs-for-menopause-wellness-accelerating-growth-of-consumer-business/ 2022-01-28T10:43:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/applied-pharmaceutical-science-inc-announces-fda-approval-of-investigational-new-drug-application-for-aps03118-a-next-generation-ret-original-new-drug-for-unlimited-cancers/ 2022-01-28T10:45:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/cryoport-and-cell-matters-enter-into-strategic-partnership/ 2022-01-28T10:48:36+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/Cryoport-Logo.jpg http://www.pharmajournalist.com/fujifilm-expands-its-advanced-therapies-cdmo-business-with-the-acquisition-of-a-dedicated-cell-therapy-manufacturing-facility-from-atara-biotherapeutics/ 2022-01-28T10:51:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/Fujifilm.jpg http://www.pharmajournalist.com/vectory-and-wageningen-university-sign-strategic-collaboration-for-the-development-of-novel-baculovirus-based-aav-production-technologies/ 2022-01-28T10:53:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/3d-cell-culture-conference-takes-place-in-less-than-2-weeks-as-a-virtual-conference/ 2022-01-31T10:45:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-368-3D-Cell-Culture-2022-300x250-VAO.jpg http://www.pharmajournalist.com/registration-is-open-for-smis-22nd-annual-pain-therapeutics-conference/ 2022-01-31T11:37:38+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-375-Pain-Therapeutics-2022-1200x627-1.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/01/P-375-Pain-Therapeutics-2022-1200x627-1.jpg http://www.pharmajournalist.com/invitation-from-the-conference-chairman-for-smis-5th-annual-pharmaceutical-microbiology-east-coast-conference/ 2022-01-31T12:01:59+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-374-Microbiology-EC-2022-1200x627-.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/01/P-374-Microbiology-EC-2022-1200x627-.jpg http://www.pharmajournalist.com/registration-is-open-for-smis-5th-annual-pharmaceutical-microbiology-east-coast-2022/ 2022-01-31T12:07:19+00:00 http://www.pharmajournalist.com/wp-content/uploads/2022/01/P-374-Microbiology-EC-2022-1200x627-.jpg http://www.pharmajournalist.com/smi-group-introduces-the-4th-annual-injectable-drug-delivery-conference-2022/ 2022-02-04T06:31:18+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/P-377-IDD-1200x627-.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/02/P-377-IDD-1200x627-.jpg http://www.pharmajournalist.com/syros-receives-fda-orphan-drug-designation-for-tamibarotene-for-the-treatment-of-mds/ 2022-02-04T07:30:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/sarepta-therapeutics-and-genedit-share-progress-on-research-collaboration-and-announce-agreement-to-develop-gene-editing-therapeutics-for-neuromuscular-diseases/ 2022-02-04T07:32:03+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Sarepta-Therapeutics.jpg http://www.pharmajournalist.com/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences-resolving-litigation-relating-to-biktarvy-and-viivs-dolutegravir-patents-and-entry-into-a-patent-licence-agreement/ 2022-02-04T07:33:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/pfizer-and-biontech-initiate-rolling-submission-for-emergency-use-authorization-of-their-covid-19-vaccine-in-children-6-months-through-4-years-of-age-following-request-from-u-s-fda/ 2022-02-04T07:35:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/oak-hill-bio-launches-with-pipeline-and-senior-leadership-from-takeda/ 2022-02-04T07:37:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation/ 2022-02-04T07:39:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/european-commission-approves-lorviqua-lorlatinib-as-a-first-line-treatment-for-alk-positive-advanced-lung-cancer/ 2022-02-04T07:42:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/aurealis-therapeutics-and-xbiome-enter-into-a-license-and-collaboration-agreement-for-aurealis-four-in-one-diabetic-foot-ulcer-and-inflammatory-disease-cell-and-gene-therapy-aup-16-in-greater-china/ 2022-02-04T07:44:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/novavax-and-israel-announce-advance-purchase-agreement-for-supply-of-covid-19-vaccine/ 2022-02-04T07:46:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/samsung-biologics-reaches-agreement-with-biogen-to-acquire-full-ownership-of-samsung-bioepis/ 2022-02-04T07:48:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/mersana-therapeutics-announces-research-collaboration-and-license-agreement-with-janssen-to-advance-novel-antibody-drug-conjugates/ 2022-02-04T07:49:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/dyve-biosciences-announces-research-and-development-collaboration-with-moffitt-cancer-center/ 2022-02-04T07:58:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/vericel-announces-plans-for-a-new-state-of-the-art-cell-therapy-manufacturing-facility-to-support-long-term-growth/ 2022-02-04T08:00:33+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/biomed-x-institute-and-merck-kgaa-darmstadt-germany-extend-collaboration-in-oncology/ 2022-02-04T08:01:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/coriolis-pharma-opens-new-atmp-formulation-development-facilities/ 2022-02-04T08:04:02+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/Coriolis-Pharma.jpg http://www.pharmajournalist.com/leica-biosystems-and-leap-therapeutics-partner-on-companion-diagnostic-to-advance-care-for-cancer-patients/ 2022-02-04T08:06:08+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/european-commission-approves-teysuno-in-metastatic-colorectal-cancer/ 2022-02-04T08:08:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/European-Commission.jpg http://www.pharmajournalist.com/alvotech-enters-exclusive-global-licensing-agreement-with-biosanapharma-for-co-development-of-a-proposed-biosimilar-avt23-to-xolair-omalizumab/ 2022-02-04T08:19:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/key-sessions-during-the-highly-potent-active-pharmaceutical-conference-released/ 2022-02-10T09:50:42+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-376-HPAPI2022-300x250-.jpg http://www.pharmajournalist.com/lilly-will-supply-up-to-600000-doses-of-bebtelovimab-to-u-s-government-in-ongoing-effort-to-provide-covid-19-treatment-options/ 2022-02-11T10:00:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/aicuris-and-hybridize-therapeutics-enter-worldwide-license-agreement-of-up-to-e100m-for-a-direct-acting-rna-based-therapy-against-bk-virus/ 2022-02-11T10:03:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ventus-therapeutics-closes-140-million-series-c-financing/ 2022-02-11T10:04:48+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/active-biotech-enters-into-global-patent-license-agreement-with-oncode-institute-for-tasquinimod-in-myelofibrosis/ 2022-02-11T10:15:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sanofi-completes-acquisition-of-amunix/ 2022-02-11T10:20:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/moderna-announces-new-supply-agreement-with-colombia-for-additional-10-8-million-doses-of-modernas-covid-19-vaccine/ 2022-02-11T10:22:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/verde-bio-holdings-announces-acquisition-in-oil-rich-permian-basin/ 2022-02-11T10:23:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/healx-and-ovid-therapeutics-to-enter-strategic-partnership/ 2022-02-11T10:25:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/teva-reaches-agreement-with-texas-to-settle-the-states-opioid-related-claims/ 2022-02-11T10:27:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/azurity-pharmaceuticals-announces-fda-approval-of-fleqsuvy-baclofen-oral-suspension/ 2022-02-11T10:30:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/biogenes-and-alphalyse-collaborate-to-optimize-elisa-reagent-characterization-for-biomanufacturing/ 2022-02-11T10:39:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/berkshire-sterile-to-offer-formulation-lyophilization-and-method-development-services/ 2022-02-11T10:42:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/LSNE-Contact-Manufacturing.jpg http://www.pharmajournalist.com/maat-pharma-and-skyepharma-have-entered-a-partnership-to-establish-the-first-exclusive-microbiome-ecosystem-therapies-cgmp-manufacturing-facility-in-france/ 2022-02-11T10:44:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/MaaT-Pharma-Logo.png http://www.pharmajournalist.com/agc-biologics-supports-omicron-based-vaccine-candidate-manufacturing-with-starting-material/ 2022-02-11T10:46:51+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/AGC-Biologics.jpg http://www.pharmajournalist.com/trirx-completes-acquisition-of-elanco-manufacturing-facility-in-speke-united-kingdom/ 2022-02-11T10:53:43+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/TriRx__Speke_Event.jpg http://www.pharmajournalist.com/piramal-pharma-solutions-strengthens-uk-presence-with-the-expansion-and-upgrade-of-its-grangemouth-and-morpeth-facilities/ 2022-02-11T10:57:49+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Piramal-Pharma-Solutions.jpg http://www.pharmajournalist.com/sartorius-completes-acquisition-of-novaseps-chromatography-division/ 2022-02-11T11:00:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/rna-therapeutics-is-at-a-critical-stage-following-the-success-of-the-covid-19-mrna-vaccines/ 2022-02-14T09:11:46+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/RNA-Social-300-%C3%97-250px.png http://www.pharmajournalist.com/pain-therapeutics-keynote-opening-addresses-from-the-pain-society-and-eptiva-therapeutics/ 2022-02-17T09:06:57+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-375-Pain-Therapeutics-2022-1200x627-1.jpg http://www.pharmajournalist.com/saphnelo-approved-in-the-eu-for-the-treatment-of-moderate-to-severe-systemic-lupus-erythematosus/ 2022-02-18T00:37:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/moderna-and-rovi-expand-long-term-collaboration-for-the-manufacture-of-mrna-medicines-over-the-next-ten-years/ 2022-02-18T00:39:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/moderna-announces-plan-to-expand-commercial-footprint-in-europe-across-six-additional-countries/ 2022-02-18T00:40:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/therapeutic-goods-administration-of-australia-authorizes-modernas-covid-19-vaccine-in-children-6-11-years/ 2022-02-18T00:42:25+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/kallyope-raises-236m-series-d-financing-to-fuel-expansion-of-novel-gut-brain-axis-therapeutic-programs/ 2022-02-18T00:43:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/immunogen-announces-a-global-multi-target-license-agreement-of-its-novel-camptothecin-adc-platform-to-lilly-for-up-to-1-7-billion/ 2022-02-18T00:45:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Immunogen-Logo.png http://www.pharmajournalist.com/pfizer-and-opkos-once-weekly-ngenla-somatrogon-injection-receives-marketing-authorization-in-european-union-for-treatment-of-pediatric-growth-hormone-deficiency/ 2022-02-18T00:47:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/axcella-therapeutics-announces-fda-fast-track-designation-for-axa1125-in-nash/ 2022-02-18T00:48:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/axcella.png http://www.pharmajournalist.com/collegium-to-acquire-biodelivery-sciences-broadening-pain-portfolio/ 2022-02-18T00:50:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/singapore-health-sciences-authority-issues-interim-authorization-for-novavax-covid-19-vaccine/ 2022-02-18T00:52:03+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/pfizer-and-biontech-provide-update-on-rolling-submission-for-emergency-use-authorization-of-their-covid-19-vaccine-in-children-6-months-through-4-years-of-age/ 2022-02-18T00:53:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/lilly-and-breast-cancer-advocacy-organizations-collaborate-to-drive-awareness-of-the-complexities-of-early-breast-cancer-and-the-risk-of-recurrence/ 2022-02-18T00:56:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/kato-wins-fda-approval-for-human-studies-of-drug-for-retinal-disorders/ 2022-02-18T00:57:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/equillium-acquires-bioniz-therapeutics-significantly-expanding-pipeline-of-novel-immunomodulatory-drug-candidates/ 2022-02-18T01:01:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/transperfect-life-sciences-and-innovaderm-research-expand-trial-interactive-partnership/ 2022-02-18T01:03:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ambrx-biopharma-announces-submission-of-ind-application-for-arx305-with-the-fda/ 2022-02-18T01:05:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/tetra-bio-pharma-enters-into-a-strategic-partnership-with-avicanna/ 2022-02-18T01:06:48+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/adcentrx-and-avantgen-enter-a-new-partnership-with-a-three-year-multi-target-collaboration-to-discover-antibodies-for-novel-antibody-drug-conjugates/ 2022-02-18T01:08:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/asymchem-acquires-snapdragon-chemistry/ 2022-02-18T01:09:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/novartis-india-limited-extends-access-to-its-medicines-in-india-by-signing-exclusive-sales-and-distribution-agreement-with-dr-reddys-laboratories/ 2022-02-18T01:11:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/bayer-receives-fda-fast-track-designation-for-asundexian-stroke-program-2/ 2022-02-18T01:12:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/quoin-pharmaceuticals-signs-exclusive-distribution-agreement-with-er-kim-for-its-lead-asset-qrx003-for-netherton-syndrome/ 2022-02-18T01:14:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-grants-fast-track-designation-to-sbt101-the-first-investigational-aav-based-gene-therapy-for-patients-with-adrenomyeloneuropathy-amn/ 2022-02-18T01:15:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-accepts-mirati-therapeutics-new-drug-application-for-adagrasib-as-treatment-of-previously-treated-krasg12c-mutated-non-small-cell-lung-cancer/ 2022-02-18T01:17:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/europes-only-parallel-trade-conference-returns-for-its-16th-year/ 2022-02-23T09:58:23+00:00 https://pharmajournalist.com/wp-content/uploads/2021/11/Parallel-Trade-Pharma-Journalist.jpg http://www.pharmajournalist.com/new-preclinical-tolebrutinib-data-demonstrated-superior-brain-penetration-and-potency/ 2022-02-25T00:32:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/sanofi.jpg http://www.pharmajournalist.com/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers/ 2022-02-25T00:34:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/enhertu-significantly-improved-both-progression-free-and-overall-survival-in-destiny-breast04-trial-in-patients-with-her2-low-metastatic-breast-cancer/ 2022-02-25T00:36:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/moderna-and-thermo-fisher-scientific-announce-long-term-strategic-collaboration/ 2022-02-25T00:39:15+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/moderna-expands-global-footprint-through-commercial-partnership-with-adium-in-latin-america/ 2022-02-25T00:40:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/moderna-initiates-phase-3-portion-of-pivotal-trial-for-mrna-respiratory-syncytial-virus-rsv-vaccine-candidate-following-independent-safety-review-of-interim-data/ 2022-02-25T00:43:18+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/code-biotherapeutics-announces-collaboration-with-takeda-to-use-proprietary-3dna-genetic-medicine-delivery-platform-to-design-and-develop-gene-therapies-for-rare-diseases/ 2022-02-25T00:46:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/actinium-pharmaceuticals-inc-and-aveo-oncology-enter-research-collaboration-agreement-to-develop-first-in-class-actinium-225-erbb3-targeting-radiotherapy-for-solid-tumors/ 2022-02-25T00:48:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biontech-and-medigene-announce-global-collaboration-to-advance-t-cell-receptor-immunotherapies-against-cancer/ 2022-02-25T00:50:24+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/BioNTech-AG.jpg http://www.pharmajournalist.com/valneva-awarded-up-to-20-million-by-scottish-enterprise-to-advance-vaccine-development/ 2022-02-25T00:51:46+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/cepi-thsti-and-panacea-biotec-partner-to-develop-broadly-protective-betacoronavirus-vaccines/ 2022-02-25T00:53:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/alvotech-and-fuji-pharma-expand-partnership-for-additional-biosimilar-candidate-in-japan/ 2022-02-25T00:56:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/algernon-pharmaceuticals-begins-manufacturing-of-repirinast-and-launches-new-chronic-kidney-disease-research-program/ 2022-02-25T00:58:25+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/LSNE-Contract-Manufacturing.jpg http://www.pharmajournalist.com/kiniksa-pharmaceuticals-and-huadong-medicine-announce-strategic-collaboration/ 2022-02-25T00:59:51+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/lilly-announces-the-institute-for-genetic-medicine-and-700-million-investment-in-boston-seaport-site/ 2022-02-25T01:01:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/prestige-biopharmas-herceptin-biosimilar-tuznue-receives-eu-gmp-certification/ 2022-02-25T01:02:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/carsgen-therapeutics-opens-new-u-s-cgmp-facility-for-car-t-production/ 2022-02-25T01:09:24+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/Carsgen-gmp.jpg https://pharmajournalist.com/wp-content/uploads/2022/02/Carsgen-gmp-1.jpg http://www.pharmajournalist.com/agilent-acquires-artificial-intelligence-technology-to-enhance-lab-productivity/ 2022-02-25T01:11:08+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/agilent-logo.png http://www.pharmajournalist.com/paige-and-flagship-biosciences-announce-partnership-to-expand-access-to-immuno-oncology-biomarkeranalysis-tools/ 2022-02-25T01:12:48+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/kato-wins-fda-approval-for-human-studies-of-drug-for-retinal-disorders-2/ 2022-02-25T01:14:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ena-respiratory-and-the-copd-foundation-partner-to-develop-pan-antiviral-nasal-spray/ 2022-02-25T01:16:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-for-cariprazine-vraylar-for-the-adjunctive-treatment-of-major-depressive-disorder/ 2022-02-25T01:17:32+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/pre-filled-syringes-east-coast-conference-now-the-biggest-ever/ 2022-02-28T10:36:44+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-373-PFS-EC-300-x-200-copy.jpg http://www.pharmajournalist.com/smi-group-introduces-the-4th-annual-injectable-drug-delivery-conference-2022-2/ 2022-03-03T09:26:42+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/P-377-IDD-300x250-.jpg http://www.pharmajournalist.com/pre-filled-syringes-west-coast-usa-conference-2022-launches/ 2022-03-03T10:12:49+00:00 http://www.pharmajournalist.com/wp-content/uploads/2022/03/P-378-PreFilled-WC-1200-x-627-.jpg http://www.pharmajournalist.com/quoin-pharmaceuticals-extends-exclusive-distribution-agreement-with-er-kim-for-its-lead-asset-qrx003-for-netherton-syndrome/ 2022-03-03T10:30:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio/ 2022-03-03T10:32:12+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/ascletis-announces-submission-of-marketing-authorization-applications-for-ritonavir-in-eight-additional-european-countries/ 2022-03-03T10:33:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/ascletis-logo.jpg http://www.pharmajournalist.com/fda-approves-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy/ 2022-03-03T10:38:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Janssen-Pharma-Logo.jpg http://www.pharmajournalist.com/purify22-chromatography-purification-conclave-promises-to-provide-unprecedented-knowledge-and-networking-opportunities/ 2022-03-04T09:46:06+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/PURIFY22-Pharma-Journalist-1.gif http://www.pharmajournalist.com/wp-content/uploads/2022/03/PURIFY-22.png http://www.pharmajournalist.com/inhibrx-receives-fda-orphan-drug-designation-for-inbrx-101-for-the-treatment-of-alpha-1-antitrypsin-deficiency/ 2022-03-04T09:57:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/beigene-announces-health-canada-approval-for-brukinsa-zanubrutinib-in-relapsed-or-refractory-marginal-zone-lymphoma/ 2022-03-04T09:59:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/correcting-and-replacing-newomics-announces-collaborations-on-high-throughput-bioanalysis/ 2022-03-04T10:01:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gc-labs-and-two-clinical-diagnostic-companies-enter-the-collaboration-for-the-new-lab-testing-service/ 2022-03-04T10:04:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ray-therapeutics-and-forge-biologics-announce-viral-vector-contract-development-and-cgmp-manufacturing-partnership/ 2022-03-04T10:06:37+00:00 https://pharmajournalist.com/wp-content/uploads/2021/07/Forge_Biologics.jpg http://www.pharmajournalist.com/amneal-enters-u-s-biosimilars-market-with-approval-of-releuko-filgrastim-ayow/ 2022-03-04T10:09:05+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/actym-therapeutics-and-wacker-biotech-sign-manufacturing-contract-for-actyms-lead-candidate-for-the-treatment-of-solid-tumors/ 2022-03-04T10:11:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/edenbridge-pharmaceuticals-announces-the-launch-of-dartisla-odt/ 2022-03-04T10:17:22+00:00 https://pharmajournalist.com/wp-content/uploads/2022/03/Edenbridge-Pharmaceuticals.png http://www.pharmajournalist.com/virios-therapeutics-announces-research-collaboration-exploring-the-potential-of-combination-antiviral-therapy-for-treating-long-covid/ 2022-03-04T10:19:24+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/taro-completes-acquisition-of-alchemee/ 2022-03-04T10:21:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizer-granted-fda-breakthrough-therapy-designation-for-rsv-vaccine-candidate/ 2022-03-04T10:51:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/virios-therapeutics-announces-research-collaboration-exploring-the-potential-of-combination-antiviral-therapy-for-treating-long-covid-2/ 2022-03-04T11:05:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-jardiance-empagliflozin-to-treat-adults-with-heart-failure-regardless-of-left-ventricular-ejection-fraction/ 2022-03-04T11:08:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/shionogi-files-for-approval-of-s-217622-a-therapeutic-drug-for-covid-19-in-japan/ 2022-03-04T11:14:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/shionogi-logo.jpg http://www.pharmajournalist.com/ema-recommends-authorisation-of-booster-doses-of-comirnaty-from-12-years-of-age/ 2022-03-04T11:18:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/European-Commission.jpg http://www.pharmajournalist.com/medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz-an-adjuvanted-plant-based-covid-19-vaccine/ 2022-03-04T11:20:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/helsinn-group-and-bridgebio-pharma-announce-update-to-strategic-collaboration-to-develop-manufacture-and-commercialize-infigratinib-in-oncology-indications-in-the-u-s/ 2022-03-04T11:29:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ 2022-03-04T11:30:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/rondo-therapeutics-closes-67-million-series-a-financing-to-advance-next-generation-immuno-oncology-platform-for-solid-tumors/ 2022-03-04T11:32:06+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/european-medicines-agency-ema-accepts-marketing-authorisation-application-for-daprodustat/ 2022-03-04T11:44:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/keytruda-pembrolizumab-plus-lenvima-lenvatinib-approved-in-japan-for-radically-unresectable-or-metastatic-renal-cell-carcinoma/ 2022-03-04T11:46:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/exclusive-chemaxon-interview-released-sponsor-at-ai-in-drug-discovery-conference-2022/ 2022-03-07T11:40:08+00:00 https://pharmajournalist.com/wp-content/uploads/2022/03/P-371-AI-in-Drug-Discovery-1200x627-Chemaxon-copy.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/03/P-371-AI-in-Drug-Discovery-1200x627-Chemaxon-copy.jpg http://www.pharmajournalist.com/rapid-microbial-methods-contamination-control-sterility-assurance-and-environmental-monitoring-to-be-covered-at-microbiology-east-coast-conference-in-boston/ 2022-03-09T10:38:27+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-374-Microbiology-EC-300x250-.jpg http://www.pharmajournalist.com/pfizer-initiates-phase-2-3-study-of-novel-covid-19-oral-treatment-in-pediatric-participants/ 2022-03-11T09:49:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/aeterna-zentaris-announces-expansion-of-research-program-with-julius-maximilians-university-wuerzburg-aiming-to-accelerate-development-of-vaccine-programs/ 2022-03-11T09:52:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/cellevolve-announces-expansive-global-collaboration-with-seattle-childrens-therapeutics-to-advance-research-for-childhood-brain-cancers/ 2022-03-11T09:58:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/insilico-medicine-enters-research-collaboration-with-the-university-of-zurich-to-apply-insilicos-generative-artificial-intelligence-platform-for-the-discovery-of-potential-therapeutics-for-cystinosi/ 2022-03-11T10:02:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/biontech-and-regeneron-expand-strategic-collaboration-to-advance-clinical-development-of-fixvac-and-libtayo-cemiplimab-combination-in-nsclc/ 2022-03-11T10:04:38+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/BioNTech-AG.jpg http://www.pharmajournalist.com/novartis-voyager-therapeutics-reach-license-option-agreement-for-next-generation-gene-therapy-vectors-for-neurological-diseases/ 2022-03-11T10:05:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/johnson-johnson-announces-landmark-agreement-to-enable-its-covid-19-vaccine-to-be-manufactured-and-made-available-by-an-african-company-for-people-living-in-africa/ 2022-03-11T10:08:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/ucb-expands-innovation-footprint-with-new-state-of-the-art-gene-therapy-facility/ 2022-03-11T10:10:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/jardiance-empagliflozin-becomes-the-first-and-only-approved-treatment-in-europe-for-adults-with-symptomatic-chronic-heart-failure-regardless-of-ejection-fraction/ 2022-03-11T10:15:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/moderna-announces-first-participant-dosed-in-phase-2-study-of-omicron-specific-bivalent-booster-candidate/ 2022-03-11T10:19:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/fda-approves-opdivo-nivolumab-with-chemotherapy-as-neoadjuvant-treatment-for-certain-adult-patients-with-resectable-non-small-cell-lung-cancer/ 2022-03-11T10:26:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/adagene-announces-safebody-multi-target-collaboration-with-sanofi-for-novel-masked-immuno-oncology-antibody-candidates/ 2022-03-11T10:30:14+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/teva-announces-launch-of-a-first-generic-version-of-revlimid-lenalidomide-capsules-in-the-u-s/ 2022-03-11T10:32:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/ucb-completes-acquisition-of-zogenix/ 2022-03-11T10:35:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/ekf-life-sciences-and-abec-partner-for-us-biomanufacturing-expansion/ 2022-03-11T10:37:13+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/aldeyra-therapeutics-initiates-phase-2-clinical-trial-of-adx-2191-for-the-treatment-of-retinitis-pigmentosa/ 2022-03-11T10:53:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/briori-biotech-granted-patent-for-topical-formulation-of-vioxx/ 2022-03-11T10:55:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/twist-bioscience-and-kriya-sign-agreement-to-discover-novel-antibodies-for-applications-in-oncology-using-gene-therapy/ 2022-03-11T10:57:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Twist-Bioscience-logo.jpg http://www.pharmajournalist.com/cerveau-technologies-inc-signs-agreement-with-roche-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research/ 2022-03-11T10:59:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-eli-lilly-and-company-to-evaluate-eras-007-and-cetuximab-combination/ 2022-03-11T11:01:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/intellia-therapeutics-receives-fda-orphan-drug-designation-for-ntla-5001-for-the-treatment-of-acute-myeloid-leukemia/ 2022-03-11T11:04:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/salubris-biotherapeutics-announces-32-million-financing-to-advance-novel-complex-biologics-for-cardiovascular-oncology-and-neurodegenerative-diseases/ 2022-03-11T11:06:12+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/microbiome-connect-is-delighted-to-announce-that-the-8th-iteration-of-the-european-summit-is-back-face-to-face-on-july-6-7-in-the-heart-of-amsterdam/ 2022-03-14T11:10:39+00:00 https://pharmajournalist.com/wp-content/uploads/2022/03/Pharma-Journalist-with-code.png http://www.pharmajournalist.com/wp-content/uploads/2022/03/Pharma-Journalist-with-code.png http://www.pharmajournalist.com/pharma-join-together-to-achieve-new-standards-in-digital-and-patient-innovation-for-clinical-transformation/ 2022-03-14T15:55:42+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/RE-Pharma-Clinical-Banner.jpg http://www.pharmajournalist.com/the-injectable-drug-delivery-conference-returns-live-and-in-person-to-london-in-may-2022/ 2022-03-14T16:08:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/SMi-Group-Ltd-Logo.png http://www.pharmajournalist.com/exclusive-speaker-interview-with-andrea-small-howard-gb-sciences-inc-released-ahead-of-the-pain-therapeutics-conference/ 2022-03-15T10:09:06+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-375-Pain-Therapeutics-2022-1200x627-1.jpg http://www.pharmajournalist.com/exclusive-speaker-interview-with-damien-boyd-msd-ahead-of-the-highly-potent-api-conference/ 2022-03-22T10:15:55+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-376-HPAPI2022-650x650-.jpg http://www.pharmajournalist.com/pre-filled-syringes-west-coast-usa-conference-2022-launches-2/ 2022-03-22T10:21:39+00:00 https://pharmajournalist.com/wp-content/uploads/2022/03/P-378-PreFilled-Wc-300-x-250-.jpg http://www.pharmajournalist.com/ligand-to-spin-off-its-omniab-business-through-merger-with-avista-public-acquisition-corp-ii/ 2022-03-24T22:01:36+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Ligand-Pharmaceuticals-logo.png http://www.pharmajournalist.com/lifemine-therapeutics-and-gsk-enter-drug-discovery-and-development-alliance/ 2022-03-24T22:03:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/sen-jam-pharmaceutical-partners-with-specialty-pharmaceutical-manufacturer-to-provide-formulation-and-chemistry-manufacturing-controls-for-covid-19-oral-therapeutic/ 2022-03-24T22:05:47+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/novavax-and-serum-institute-of-india-announce-first-emergency-use-authorization-of-novavax-covid-19-vaccine-in-adolescents-%e2%89%a512-to/ 2022-03-24T22:07:42+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/pfizer-to-supply-unicef-up-to-4-million-treatment-courses-of-novel-covid-19-oral-treatment-for-low-and-middle-income-countries/ 2022-03-24T22:10:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/teva-reaches-agreement-with-rhode-island-to-settle-opioid-related-claims/ 2022-03-24T22:14:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/nice-recommends-elosulfase-alfa-for-routine-nhs-use-for-patients-with-rare-life-limiting-metabolic-disorder/ 2022-03-24T22:16:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/NICE-Cancer-Drug-nivolumab.jpg http://www.pharmajournalist.com/apexigen-and-brookline-capital-acquisition-corp-announce-business-combination-agreement-to-create-publicly-listed-immuno-oncology-company/ 2022-03-24T22:17:53+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/Apexigen-Logo.png http://www.pharmajournalist.com/lynk-pharmaceuticals-and-simcere-announced-strategic-commercialization-partnership-upon-novel-jak1-inhibitor-lnk01001/ 2022-03-24T22:19:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/centogene-announces-expansion-of-data-access-and-collaboration-agreement-with-pfizer/ 2022-03-24T22:22:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/saniona-ion-channel-research-collaboration-with-boehringer-ingelheim-advances-to-next-stage/ 2022-03-24T22:25:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/wockhardt-and-serum-life-sciences-uk-announce-collaboration-for-manufacturing-multiple-vaccines-in-the-united-kingdom/ 2022-03-24T22:30:49+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Wockhardt.jpg http://www.pharmajournalist.com/neurosense-therapeutics-receives-fda-clearance-of-ind-for-primec-for-the-treatment-of-als/ 2022-03-24T22:33:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/acasti-pharma-announces-patents-for-gtx-104-in-europe-gtx-102-in-the-u-s-and-gtx-101-in-japan/ 2022-03-24T22:36:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/acasti-pharma-logo.png http://www.pharmajournalist.com/proscia-and-visiopharm-partner-to-deliver-ai-powered-pathology-to-drive-insight-in-cancer-diagnosis/ 2022-03-24T22:46:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/quest-diagnostics-granted-cdc-contract-to-support-covid-19-infection-and-vaccination-seroprevalence-research/ 2022-03-24T22:50:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/cyclica-and-arctoris-to-expand-partnership-to-advance-drug-discovery-programs-for-alzheimers-disease/ 2022-03-24T22:51:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/lifemine-therapeutics-announces-175-million-series-c-financing/ 2022-03-24T22:57:29+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/affini-t-therapeutics-completes-175-million-financing-co-led-by-vida-ventures-and-leaps-by-bayer-to-advance-groundbreaking-t-cell-therapies-for-solid-tumor-patients-with-oncogenic-driver-mutations/ 2022-03-24T23:07:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-msi%e2%80%91h-dmmr-advanced-endometrial-carcinoma/ 2022-03-24T23:08:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/bristol-myers-squibb-gets-fda-approval-for-metastatic-melanoma-therapy/ 2022-03-24T23:32:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/the-injectable-drug-delivery-conference-is-fast-approaching-and-features-the-leading-lights-in-the-industry/ 2022-03-25T10:08:57+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/P-377-IDD-300x250-.jpg http://www.pharmajournalist.com/pre-filled-syringes-east-coast-conference-space-now-limited/ 2022-03-25T10:16:24+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/P-373-PFS-EC-300-x-200-copy.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-roches-actemra-roactemra-for-the-treatment-of-covid-19-in-hospitalised-adults/ 2022-04-04T08:47:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/new-data-for-roches-ocrevus-ocrelizumab-show-benefit-in-disability-progression-and-cognitive-decline-in-both-secondary-progressive-and-primary-progressive-multiple-sclerosis/ 2022-04-04T08:49:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/novartis-announces-european-commission-approval-of-beovu-for-people-living-with-diabetic-macular-edema/ 2022-04-04T08:51:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/northeastern-university-and-copernicus-therapeutics-inc-awarded-14-7-million-nida-nih-grant-to-develop-a-gene-therapy-approach-for-treating-opioid-use-disorder/ 2022-04-04T08:52:55+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/novavax-submits-request-to-expand-conditional-marketing-authorization-of-covid-19-vaccine-in-the-european-union-to-adolescents-ages-12-17/ 2022-04-04T08:54:47+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/teva-reaches-agreement-with-florida-to-settle-the-states-opioid-related-claims/ 2022-04-04T08:56:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/TEVA-Pharma.jpg http://www.pharmajournalist.com/neuron23-closes-100-million-series-c-financing-round-nominates-clinical-candidate-for-parkinsons-disease/ 2022-04-04T08:58:22+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/cytodyn-announces-partial-clinical-hold-of-hiv-program-and-full-clinical-hold-of-covid-19-program/ 2022-04-04T09:05:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/Cytodyn-Logo.jpg http://www.pharmajournalist.com/pfizer-and-biontech-receive-expanded-u-s-emergency-use-authorization-for-an-additional-covid-19-vaccine-booster-in-individuals-aged-50-years-and-older/ 2022-04-04T09:07:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/eagle-pharmaceuticals-agrees-to-terms-to-acquire-acacia-pharma-group-plc/ 2022-04-04T09:09:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/eagle-pharmaceuticals-logo.png http://www.pharmajournalist.com/sanofi-and-igm-biosciences-announce-collaboration-agreement-for-oncology-immunology-and-inflammation-targets/ 2022-04-04T09:11:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/evusheld-long-acting-antibody-combination-approved-in-the-eu-for-pre-exposure-prophylaxis-prevention-of-covid-19-in-a-broad-population/ 2022-04-04T09:13:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/european-medicines-agency-commences-review-of-novel-gene-therapy-candidate-etranacogene-dezaparvovec-for-people-with-hemophilia-b/ 2022-04-04T09:15:13+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/CSL-Behring.png http://www.pharmajournalist.com/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china/ 2022-04-04T09:17:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/ono-enters-into-a-development-and-license-agreement-with-numab/ 2022-04-04T09:19:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sellas-life-sciences-signs-exclusive-license-agreement-with-genfleet-therapeutics-for-next-generation-highly-selective-cdk9-inhibitor/ 2022-04-04T09:21:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/receptor-life-sciences-announces-fda-acceptance-of-ind-application-for-rls103-inhaled-dry-powder-cbd-and-initiation-of-ind-opening-clinical-safety-and-efficacy-study/ 2022-04-04T09:23:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/rentschler-biopharma-and-vetter-unveil-xpert-alliance-a-joint-visualization-of-their-successful-strategic-collaboration/ 2022-04-04T09:25:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-launches-ce-ivd-marked-next-generation-sequencing-instrument-for-use-in-clinical-labs/ 2022-04-04T09:27:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/fda-keynote-speaker-at-smis-5th-annual-pharmaceutical-microbiology-east-coast-conference-in-boston-usa/ 2022-04-07T10:25:45+00:00 https://pharmajournalist.com/wp-content/uploads/2022/04/P-374-Microbiology-EC-1200x627-LC3WK-.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/04/P-374-Microbiology-EC-1200x627-LC3WK-.jpg http://www.pharmajournalist.com/pregene-enters-into-innovative-partnership-with-cellpoint-to-develop-anti-bcma-car-t-cell-therapy-in-europe-and-the-us/ 2022-04-08T07:32:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/beigene-announces-european-medicines-agency-acceptance-of-marketing-authorization-applications-for-tislelizumab-for-the-treatment-of-patients-with-escc-and-nsclc/ 2022-04-08T07:34:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/everest-medicines-enters-into-an-mou-for-partnership-with-china-resources-pharmaceutical-group-for-its-mrna-vaccine-business/ 2022-04-08T07:35:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/exclusive-speaker-interview-with-ester-lovsin-barle-ahead-of-the-6th-annual-highly-potent-active-pharmaceutical-ingredients-conference/ 2022-04-11T10:07:41+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-376-HPAPI2022-650x650-.jpg http://www.pharmajournalist.com/exclusive-speaker-interview-with-aobiome-ahead-of-the-22nd-pain-therapeutics-conference/ 2022-04-13T14:54:01+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/P-375-Pain-Therapeutics-2022-1200x627-1.jpg http://www.pharmajournalist.com/only-4-weeks-to-go-until-injectable-drug-delivery-in-london/ 2022-04-14T14:32:06+00:00 https://pharmajournalist.com/wp-content/uploads/2022/02/P-377-IDD-300x250-.jpg http://www.pharmajournalist.com/halozyme-to-acquire-antares-pharma-to-create-a-specialty-product-and-drug-delivery-leader/ 2022-04-15T12:39:59+00:00 https://pharmajournalist.com/wp-content/uploads/2019/05/Halozyme-Logo.png http://www.pharmajournalist.com/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-1-9bn/ 2022-04-15T12:41:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/lysogene-enters-into-an-exclusive-worldwide-license-agreement-with-yeda/ 2022-04-15T13:13:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/juniper-biologics-acquires-cell-mediated-gene-therapy-tg-c-ld-for-treatment-of-knee-osteoarthritis/ 2022-04-15T13:15:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-grants-direct-biologics-regenerative-medicine-advanced-therapy-rmat-designation-for-the-use-of-exoflo-in-covid-19-related-ards/ 2022-04-15T13:18:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/opus-enters-strategic-collaboration-with-resilience-for-aav-based-gene-therapy-development-and-manufacturing-for-inherited-retinal-diseases/ 2022-04-15T13:20:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/kyttaro-announces-worldwide-exclusive-licensing-agreement-with-lilly-for-antibody-therapeutic-program/ 2022-04-15T13:21:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/engitix-announces-expanded-collaboration-and-licensing-agreement-with-takeda-to-develop-new-anti-fibrotic-therapies-in-inflammatory-bowel-disease/ 2022-04-15T13:23:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/telix-announces-licence-agreement-with-lilly-for-olaratumab/ 2022-04-15T13:24:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/novavax-and-serum-institute-of-india-receive-emergency-use-authorization-for-novavax-covid-19-vaccine-in-thailand/ 2022-04-15T13:26:57+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/moderna-announces-first-participants-dosed-in-phase-1-2-study-with-mrna-1020-and-mrna-1030-seasonal-influenza-vaccine-candidates/ 2022-04-15T13:28:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/jazz-pharmaceuticals-and-werewolf-therapeutics-announce-exclusive-global-license-and-collaboration-agreement-to-develop-wtx-613-a-differentiated-conditionally-activated-ifn%ce%b1-indukine-molecule/ 2022-04-15T13:30:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/jazz-pharmaceuticals.jpg http://www.pharmajournalist.com/pfizer-and-biontech-announce-data-demonstrating-high-immune-response-following-a-booster-dose-of-their-covid-19-vaccine-in-children-5-through-11-years-of-age/ 2022-04-15T13:31:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19/ 2022-04-15T13:34:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/scirhom-starts-cmc-development-of-its-first-drug-candidate-for-clinical-development/ 2022-04-15T13:36:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/bioasis-enters-into-research-collaboration-with-janssen/ 2022-04-15T13:37:37+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/bioasis-Logo.jpg http://www.pharmajournalist.com/achilles-therapeutics-announces-manufacturing-expansion-in-the-uk-and-partnership-for-manufacturing-in-the-us/ 2022-04-15T13:39:06+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/Achilles-Therapeutics.jpg http://www.pharmajournalist.com/persephone-biosciences-and-ginkgo-bioworks-announce-collaboration-to-develop-novel-therapeutics/ 2022-04-15T13:40:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/atyr-pharma-announces-fda-orphan-drug-designation-for-efzofitimod-atyr1923-for-treatment-of-systemic-sclerosis/ 2022-04-15T13:41:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/01/atyr-logo.png http://www.pharmajournalist.com/european-commission-approves-padcev-enfortumab-vedotin-for-locally-advanced-or-metastatic-urothelial-cancer/ 2022-04-15T13:44:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/ardelyx-and-kyowa-kirin-amend-license-agreement-for-tenapanor/ 2022-04-15T13:46:00+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/ardelyx-logo.png http://www.pharmajournalist.com/glenmark-specialty-s-a-receives-approval-for-conducting-phase-1-clinical-trial-of-its-novel-molecule-grc-54276-in-patients-with-advanced-solid-tumors-and-hodgkins-lymphoma/ 2022-04-15T13:48:55+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Glenmark-Pharma-Image.jpg http://www.pharmajournalist.com/harbour-biomed-announces-global-out-license-agreement-with-astrazeneca-for-cldn18-2xcd3-bispecific-antibody-hbm7022/ 2022-04-15T13:50:41+00:00 https://pharmajournalist.com/wp-content/uploads/2019/06/Harbour-BioMed-Logo.jpg http://www.pharmajournalist.com/exclusive-speaker-interview-with-stefano-zanotti-head-of-neuromuscular-research-at-dyne-therapeutics/ 2022-04-21T10:57:17+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/RNA-Social-300-%C3%97-250px.png http://www.pharmajournalist.com/dragonfly-therapeutics-announces-multi-target-expansion-of-its-research-collaboration-with-abbvie-to-develop-novel-therapeutic-candidates-for-immune-mediated-diseases/ 2022-04-22T05:29:16+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/health-canada-grants-marketing-authorization-for-trikafta-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-6-through-11-years-with-at-least-one-f508del-mutation/ 2022-04-22T05:30:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/health-canada-logo.jpg http://www.pharmajournalist.com/samsung-biologics-completes-full-acquisition-of-samsung-bioepis/ 2022-04-22T05:32:41+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/Samsung-BioLogics.jpg http://www.pharmajournalist.com/labcorp-enhances-cell-and-gene-therapy-development-support-through-collaboration-with-xcell-biosciences/ 2022-04-22T05:34:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/LabCorp.jpg http://www.pharmajournalist.com/regeneron-to-acquire-checkmate-pharmaceuticals-and-its-investigational-immune-activator-for-potential-use-in-multiple-tumor-types/ 2022-04-22T05:35:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/takeda-announces-approval-of-nuvaxovid-covid-19-vaccine-for-primary-and-booster-immunization-in-japan/ 2022-04-22T08:10:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/ocugen-inc-to-commercialize-covaxin-in-mexico-rights-now-encompassing-all-of-north-america/ 2022-04-22T08:14:25+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/Ocugen_Logo.jpg http://www.pharmajournalist.com/fda-extends-review-of-biologics-license-application-for-regen-cov-casirivimab-and-imdevimab-for-treatment-and-prophylaxis-of-covid-19/ 2022-04-22T08:16:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/china-nmpa-approves-tislelizumab-for-patients-with-second-line-esophageal-squamous-cell-carcinoma/ 2022-04-22T08:18:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/enzyvant-announces-plans-to-expand-regenerative-medicine-manufacturing-capabilities/ 2022-04-22T08:20:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/codexis-and-seqwell-announce-strategic-investment-and-partnership-initiation/ 2022-04-22T08:22:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/codexis-inc-logo.jpg http://www.pharmajournalist.com/abbvie-terminates-collaboration-with-bioarctic-on-alpha-synuclein-portfolio/ 2022-04-22T08:24:14+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-opens-bioprocessing-manufacturing-site-in-ogden-utah/ 2022-04-22T08:25:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-enhances-clinical-research-solutions-in-collaboration-with-matrix-clinical-trials/ 2022-04-22T08:27:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/asahi-kasei-medical-to-acquire-bionova-scientific-u-s-based-biopharmaceutical-cdmo/ 2022-04-22T08:28:25+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ankyra-therapeutics-announces-cooperative-research-and-development-agreement-with-the-national-cancer-institute/ 2022-04-22T08:29:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/halozyme-to-acquire-antares-pharma-to-create-a-specialty-product-and-drug-delivery-leader-2/ 2022-04-22T08:31:04+00:00 https://pharmajournalist.com/wp-content/uploads/2019/05/Halozyme-Logo.png http://www.pharmajournalist.com/dndi-and-benevolentai-collaborate-to-accelerate-life-saving-drug-discovery-research-in-dengue/ 2022-04-22T08:32:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/benevolentAI.jpg http://www.pharmajournalist.com/kite-receives-u-s-fda-approval-of-new-state-of-the-art-car-t-cell-therapy-manufacturing-facility-in-maryland/ 2022-04-22T08:33:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/biocytogen-enters-agreement-with-ctm-bio-to-co-develop-tcr-mimic-antibody-based-multi-specific-t-cell-engagers/ 2022-04-22T08:35:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sqz-biotechnologies-receives-fda-fast-track-designation-for-its-lead-cell-therapy-candidate-for-the-treatment-of-hpv16-tumors/ 2022-04-29T10:13:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/valneva-provides-regulatory-update-on-its-inactivated-covid-19-vaccine-candidate/ 2022-04-29T10:15:47+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/isleworth-healthcare-acquisition-corp-and-cytovia-therapeutics-announce-agreement-for-business-combination-to-create-publicly-listed-company-focused-on-empowering-natural-killer-cell-therapeutics-to/ 2022-04-29T10:17:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/pfizer-and-biontech-submit-application-for-u-s-emergency-use-authorization-for-a-covid-19-vaccine-booster-dose-in-children-5-through-11-years-of-age/ 2022-04-29T10:19:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/university-of-tokyo-astellas-enter-second-phase-of-strategic-partnership-for-co-creation-of-innovative-new-medicines-and-medical-solutions/ 2022-04-29T10:22:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/veklury-remdesivir-is-first-and-only-approved-treatment-for-pediatric-patients-under-12-years-of-age-with-covid-19/ 2022-04-29T10:23:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/porton-advanced-and-sinorda-biomedicine-enter-strategic-collaboration-to-accelerate-cell-therapy-development-for-solid-tumors/ 2022-04-29T10:31:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gc-biopharma-concludes-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-delivery-system-for-use-in-mrna-vaccines-and-therapeutics/ 2022-04-29T10:33:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/abbvie-and-plexium-enter-into-multi-target-strategic-collaboration-to-develop-and-commercialize-targeted-protein-degradation-therapies-for-neurological-conditions/ 2022-04-29T10:35:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/serenity-bioworks-acquires-dc-tab-for-lupus-nephritis/ 2022-04-29T10:36:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/virpax-successfully-completes-initial-preclinical-studies-for-vrp324/ 2022-04-29T10:38:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/castle-biosciences-completes-acquisition-of-altheadx/ 2022-04-29T10:39:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Castlecreekpharma.jpg http://www.pharmajournalist.com/rvac-medicines-a-cbc-incubated-mrna-platform-company-raises-us140-million-to-expand-rd-and-manufacturing-capacity/ 2022-04-29T10:41:13+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/turnstone-biologics-announces-til-therapy-research-collaboration-with-the-university-of-montreal-hospital-research-centre/ 2022-04-29T10:43:18+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/breckenridge-signs-new-product-agreement-with-pts-pharma/ 2022-04-29T10:44:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/pfizer-and-biohavens-vydura-rimegepant-granted-first-ever-marketing-authorization-by-european-commission-for-both-acute-treatment-of-migraine-and-prophylaxis-of-episodic-migraine/ 2022-04-29T10:50:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/enhertu-granted-breakthrough-therapy-designation-in-u-s-for-patients-with-her2-low-metastatic-breast-cancer/ 2022-04-29T10:52:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/tremelimumab-accepted-under-priority-review-in-the-us-for-patients-with-unresectable-liver-cancer-in-combination-with-imfinzi/ 2022-04-29T10:54:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/chmp-recommends-eu-approval-of-roches-tecentriq-as-adjuvant-treatment-for-a-subset-of-people-with-early-stage-non-small-cell-lung-cancer/ 2022-04-29T10:56:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/amphista-therapeutics-enters-strategic-collaboration-with-merck-for-discovery-and-development-of-targeted-protein-degradation-therapeutics/ 2022-05-06T09:55:46+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/novartis-kymriah-receives-ec-approval-as-first-car-t-cell-therapy-for-adults-with-relapsed-or-refractory-follicular-lymphoma/ 2022-05-06T09:57:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/novavax-requests-expanded-authorization-of-nuvaxovid-covid-19-vaccine-to-adolescents-aged-12-through-17-years-in-great-britain/ 2022-05-06T10:00:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/genesis-therapeutics-announces-strategic-collaboration-with-lilly-to-discover-novel-therapies-using-the-genesis-molecular-ai-platform/ 2022-05-06T10:02:21+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/Genesis-Therapeutics-Logo.jpg http://www.pharmajournalist.com/storm-therapeutics-awarded-innovate-uk-grant-to-discover-and-develop-a-novel-coronavirus-therapy-targeting-an-rna-modifying-enzyme/ 2022-05-06T10:04:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/horizon-therapeutics-plc-receives-european-commission-ec-approval-of-uplizna-inebilizumab-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd/ 2022-05-06T10:06:05+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/Horizon-Therapeutics-Logo.jpg http://www.pharmajournalist.com/rinvoq-upadacitinib-approved-by-fda-as-an-oral-treatment-for-adults-with-active-ankylosing-spondylitis/ 2022-05-06T10:07:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-chooses-cerebras-systems-to-accelerate-ai-biopharmaceutical-research/ 2022-05-06T10:10:24+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/algernon-pharmaceuticals-announces-last-patient-treated-in-phase-2-study-of-ipf-and-chronic-cough/ 2022-05-06T10:13:00+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/Algernon-Pharma-Logo.png http://www.pharmajournalist.com/brickell-biotech-announces-sale-of-sofpironium-bromide-to-botanix-pharmaceuticals/ 2022-05-06T10:14:49+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/stevanato-group-and-owen-mumford-sign-exclusive-collaboration-agreement-for-the-innovative-aidaptus-auto-injector/ 2022-05-06T10:16:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/cytena-and-excellgene-to-develop-automated-workflows-for-biotherapeutics-cell-line-development/ 2022-05-06T10:18:46+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/agastiya-biotech-receives-fda-orphan-drug-designation-for-ab001-for-pancreatic-cancer-and-acute-myeloid-leukemia-aml/ 2022-05-06T10:20:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/endo-acquires-six-development-stage-ready-to-use-injectable-product-candidates-from-nevakar/ 2022-05-06T10:21:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/07/endo-logo.png http://www.pharmajournalist.com/nicoya-completes-acquisition-of-lsk-technologies-expanding-digital-platform-into-molecular-testing/ 2022-05-06T10:22:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/inmagene-receives-fdas-ind-clearance-for-ox40-antagonist/ 2022-05-06T10:23:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novartis-receives-european-commission-approval-for-jakavi-to-be-the-first-post-steroid-treatment-for-acute-and-chronic-graft-versus-host-disease/ 2022-05-06T10:26:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/apnimed-announces-62-5-million-series-c-financing-to-advance-development-of-novel-pharmaceutical-treatments-for-obstructive-sleep-apnea-osa-and-related-sleep-disorders/ 2022-05-06T10:27:34+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/sapience-therapeutics-receives-fda-orphan-drug-designation-for-st101-for-the-treatment-of-advanced-melanoma/ 2022-05-06T10:28:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/intravacc-signs-an-exclusive-license-agreement-with-zhifei-lvzhu-biopharmaceutical-to-commercialize-avacc-3-an-omv-based-whooping-cough-vaccine/ 2022-05-06T10:30:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/supernus-announces-fda-approval-of-qelbree-for-the-treatment-of-adhd-in-adults/ 2022-05-06T10:33:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/mrna-based-therapeutics-summit-is-returning-to-boston-this-july/ 2022-05-09T12:25:14+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/mRNA-Based-Therapeutics-social-post.png http://www.pharmajournalist.com/wp-content/uploads/2022/05/mRNA-Based-Therapeutics-social-post.png http://www.pharmajournalist.com/pre-filled-syringes-west-coast-takes-place-in-a-months-time/ 2022-05-11T08:00:21+00:00 https://pharmajournalist.com/wp-content/uploads/2019/01/Pharma-Micro-West-Coast-2020-Pharma-Journalist.jpg http://www.pharmajournalist.com/registration-is-now-open-for-oligonucleotide-therapeutics-and-delivery-conference/ 2022-05-11T08:20:28+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/P-382-Conference-Chairs-.jpg https://pharmajournalist.com/wp-content/uploads/2022/05/P-382-Conference-Chairs-.jpg http://www.pharmajournalist.com/sound-pharmaceuticals-nih-grant-for-a-novel-oral-covid-19-treatment-increases-to-4-2m/ 2022-05-13T09:33:19+00:00 https://pharmajournalist.com/wp-content/uploads/2021/04/Sound-Pharma-Logo.jpg http://www.pharmajournalist.com/fda-approves-lilly-and-incytes-olumiant-baricitinib-for-the-treatment-of-certain-hospitalized-patients-with-covid-19/ 2022-05-13T09:35:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/eiger-biopharmaceuticals-and-anges-announce-exclusive-partnership-for-regulatory-approval-and-commercialization-of-zokinvy-lonafarnib-in-japan/ 2022-05-13T09:37:40+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizer-to-acquire-biohaven-pharmaceuticals/ 2022-05-13T09:45:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/twist-bioscience-enters-into-research-exclusive-option-and-license-agreement-with-astellas-for-antibodies-to-reduce-tumor-microenvironment-mediated-immunosuppression/ 2022-05-13T09:46:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/robert-wessman-led-aztiq-completes-500-million-transaction-in-an-alliance-with-innobic-to-create-an-international-pharma-powerhouse/ 2022-05-13T09:48:04+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/janssen-discontinues-collaboration-and-license-agreements-with-bavarian-nordic-in-hepatitis-b-and-human-papillomavirus/ 2022-05-13T09:49:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Janssen-Pharma-Logo.jpg http://www.pharmajournalist.com/myovant-sciences-and-pfizer-provide-update-on-supplemental-new-drug-application-snda-for-myfembree-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis/ 2022-05-13T09:51:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/orion-enters-into-exclusive-agreement-with-jemincare-for-novel-non-opioid-drug-candidate-for-the-treatment-of-pain/ 2022-05-13T09:53:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/advanz-pharma-to-acquire-intercepts-business-in-europe-canada-and-all-other-markets-outside-of-the-u-s/ 2022-05-13T09:55:24+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/illumina-and-deerfield-management-partner-to-accelerate-drug-development/ 2022-05-13T09:57:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/neurocrine-biosciences-receives-orphan-drug-designation-for-valbenazine-as-a-treatment-for-chorea-associated-with-huntington-disease/ 2022-05-13T09:58:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Neurocrine-Biosciences.jpg http://www.pharmajournalist.com/mindset-pharma-progresses-plans-for-clinical-trials-of-its-advanced-pre-clinical-psychedelic-msp-1014/ 2022-05-13T10:00:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/nuvig-launches-to-develop-novel-immune-therapeutics-for-chronic-inflammatory-and-autoimmune-diseases/ 2022-05-13T10:02:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/neuvivo-begins-manufacturing-of-np001-for-treatment-of-als/ 2022-05-13T10:03:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/drug-discovery.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-introduces-qualtrak-biopharma-qpcr-solutions-to-streamline-biologics-development-and-compliance/ 2022-05-13T10:05:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/opko-health-acquires-modex-therapeutics-gains-proprietary-immunotherapy-technology-with-a-focus-on-oncology-and-infectious-diseases/ 2022-05-13T10:06:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/hitachi-high-tech-and-invivoscribe-partner-to-advance-molecular-diagnostics-and-precision-medicine/ 2022-05-13T10:08:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/citius-pharmaceuticals-to-accelerate-phase-3-mino-lok-trial-by-expanding-trial-sites-internationally/ 2022-05-13T10:09:30+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/Citius-Pharma-Logo.png http://www.pharmajournalist.com/stealth-biotherapeutics-receives-orphan-drug-designation-from-fda-for-elamipretide-for-treatment-of-duchenne-muscular-dystrophy/ 2022-05-13T10:11:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/stealth-biotherapeutics-logo.png http://www.pharmajournalist.com/artax-biopharma-closes-financing-to-advance-clinical-stage-first-in-class-oral-immunomodulator-to-treat-t-cell-mediated-diseases/ 2022-05-13T10:12:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/moma-therapeutics-announces-150-million-series-b-financing/ 2022-05-13T10:14:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/gns-healthcare-and-arvinas-enter-into-neuroscience-drug-discovery-collaboration/ 2022-05-13T10:16:25+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/inxmed-raised-15-million-in-series-b-financing-to-advance-innovative-therapies-to-drug-resistant-cancers/ 2022-05-13T10:17:42+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/event-launch-pre-filled-syringes-san-francisco-conference/ 2022-05-18T08:20:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/laekna-therapeutics-raises-61-million-in-series-d-financing/ 2022-05-20T09:11:46+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/postera-spearheads-ai-driven-drug-discovery-collaboration-to-develop-antiviral-therapeutics-with-initial-68m-in-nih-funding/ 2022-05-20T09:13:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/ascentage-pharma-announces-preclinical-data-demonstrating-olverembatinibs-therapeutic-potential-in-treating-covid-19-published-in-embo-molecular-medicine/ 2022-05-20T09:23:51+00:00 https://pharmajournalist.com/wp-content/uploads/2018/12/Ascentage-Pharma.png http://www.pharmajournalist.com/sernova-and-evotec-enter-into-an-exclusive-global-strategic-partnership-for-ipsc-based-beta-cell-replacement-therapy-to-develop-and-commercialize-a-functional-cure-for-diabetes/ 2022-05-20T09:26:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizer-and-biontech-granted-u-s-emergency-use-authorization-for-booster-dose-of-their-covid-19-vaccine-in-children-5-through-11-years-of-age/ 2022-05-20T09:27:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/abbvie-and-cugene-announce-collaboration-in-autoimmune-diseases/ 2022-05-20T09:28:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/kriya-announces-270-million-series-c-financing-to-advance-fully-integrated-gene-therapy-engine/ 2022-05-20T09:30:24+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-approves-lillys-mounjaro-tirzepatide-injection-the-first-and-only-gip-and-glp-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes/ 2022-05-20T09:32:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/valneva-receives-notice-of-european-commissions-intent-to-terminate-covid-19-vaccine-purchase-agreement/ 2022-05-20T09:33:25+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/pfizer-and-biontech-provide-update-on-covid-19-vaccine-supply-agreement-with-european-commission/ 2022-05-20T09:34:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/editas-medicine-receives-fda-orphan-drug-designation-for-edit-301-for-the-treatment-of-beta-thalassemia/ 2022-05-20T09:36:10+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Editas-Medicine-Logo.png http://www.pharmajournalist.com/inmagene-receives-fda-ind-clearance-for-a-third-generation-btk-inhibitor-targeting-immunological-diseases/ 2022-05-20T09:39:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca/ 2022-05-20T09:40:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/perkinelmer-expands-genomic-testing-services-with-ultrarapid-whole-genome-sequencing/ 2022-05-20T09:42:03+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/perkinelmer.png http://www.pharmajournalist.com/proscia-introduces-ai-powered-quality-control-to-accelerate-data-driven-drug-development/ 2022-05-20T09:45:24+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/Proscia-Logo.jpg http://www.pharmajournalist.com/astrazeneca-signs-licence-agreement-with-rq-biotechnology-for-monoclonal-antibodies-against-covid-19/ 2022-05-20T09:46:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/zealand-pharma-announces-asset-purchase-agreement-with-mannkind-corporation-for-v-go-insulin-delivery-device/ 2022-05-20T09:47:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/tonix-pharmaceuticals-extends-research-collaboration-with-the-university-of-alberta-to-develop-antiviral-drugs-against-sars-cov-2/ 2022-05-20T09:49:00+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/tonix-pharmaceuticals.png http://www.pharmajournalist.com/simcere-pharma-novel-inhibitor-of-covid-19-3clpro-sim0417-received-a-second-clinical-trial-approval-in-china/ 2022-05-20T09:50:13+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Covid-19.jpg http://www.pharmajournalist.com/sinclair-pharma-partners-with-vanguard-aesthetics-to-launch-silhouette-soft-in-malaysia/ 2022-05-20T09:52:11+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/swanbio-therapeutics-announces-56-million-series-b-financing-to-advance-novel-gene-therapies-for-neurological-conditions/ 2022-05-20T09:54:51+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/swanbio-logo.jpg http://www.pharmajournalist.com/statera-biopharma-and-lay-sciences-inc-announce-intent-to-enter-strategic-partnership-to-license-the-manufacturing-rights-to-certain-lay-sciences-igy-products/ 2022-05-20T09:56:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/purify22-takes-chromatography-purification-notches-higher-industry-rallies-around-this-mega-event/ 2022-05-20T12:13:25+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/PURIFY22-Pharma-Journalist-MU070322.gif http://www.pharmajournalist.com/sae-media-group-announces-the-date-for-2nd-annual-aseptic-processing-conference/ 2022-05-23T11:26:03+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/P-381-Aseptic-Processing-2022-300x250-in-person-copy.jpg http://www.pharmajournalist.com/early-bird-discount-finishes-on-31-may-2022-for-the-pre-filled-syringes-san-francisco-conference/ 2022-05-24T09:21:23+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/Pre-Filled-Syringes-San-Fran.jpg http://www.pharmajournalist.com/servier-announces-fda-approval-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-newly-diagnosed-idh1-mutated-acute-myeloid-leukemia/ 2022-05-26T20:50:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/hyundai-bioscience-to-request-a-fast-track-processing-for-its-monkeypox-treatment-drug-with-the-fda/ 2022-05-26T20:51:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/lilly-plans-to-invest-2-1-billion-in-new-manufacturing-sites-in-indiana/ 2022-05-26T20:53:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/insilico-medicine-announces-novel-3cl-protease-inhibitor-preclinical-candidate-for-covid-19-treatment/ 2022-05-26T20:54:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/st-johns-researcher-awarded-nih-grant-to-create-inhalable-covid-19-vaccine/ 2022-05-26T20:56:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Covid-19.jpg http://www.pharmajournalist.com/european-commission-approves-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment/ 2022-05-26T20:57:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/merck-group.jpg http://www.pharmajournalist.com/innoviva-to-acquire-entasis-therapeutics/ 2022-05-26T20:59:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata-aa/ 2022-05-26T21:00:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/abbvie-submits-new-drug-application-to-fda-for-investigational-abbv-951-foscarbidopa-foslevodopa-for-the-treatment-of-advanced-parkinsons-disease/ 2022-05-26T21:02:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/abbvie.jpg http://www.pharmajournalist.com/atara-biotherapeutics-provides-update-on-strategic-collaboration-with-bayer/ 2022-05-26T21:03:35+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Atara-Bio_logo.png http://www.pharmajournalist.com/be-bio-and-resilience-announce-strategic-collaboration-to-manufacture-engineered-b-cells-a-new-class-of-cellular-medicines/ 2022-05-26T21:04:53+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ptc-therapeutics-receives-positive-chmp-opinion-for-upstaza-for-the-treatment-of-aadc-deficiency/ 2022-05-26T21:07:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/PTC-Therapeutics.jpg http://www.pharmajournalist.com/medison-pharma-announces-extension-of-multi-territorial-agreement-with-immunocore-and-expansion-into-australia-and-new-zealand/ 2022-05-26T21:08:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ocugen-announces-fda-removes-clinical-hold-on-phase-2-3-clinical-trial-for-covaxin-bbv152/ 2022-05-26T21:09:41+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/Ocugen_Logo.jpg http://www.pharmajournalist.com/amphastar-receives-fda-approval-for-regadenoson/ 2022-05-26T21:11:08+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/Amphastar.jpg http://www.pharmajournalist.com/halozyme-completes-antares-pharma-acquisition/ 2022-05-26T21:12:21+00:00 https://pharmajournalist.com/wp-content/uploads/2019/05/Halozyme-Logo.png http://www.pharmajournalist.com/genomic-testing-cooperative-hematology-profile-plus-solid-tumor-profile-plus-and-liquid-biopsy-profiles-receive-ce-ivd-mark/ 2022-05-26T21:15:31+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/Genomic-Testing-Logo.png http://www.pharmajournalist.com/castle-creek-biosciences-raises-112-8-million-to-advance-novel-gene-therapies-and-expand-pipeline/ 2022-05-26T21:17:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Castlecreekpharma.jpg http://www.pharmajournalist.com/european-medicines-agency-grants-orphan-drug-designation-to-cornerstone-pharmaceuticals-cpi-613-devimistat-for-treatment-of-patients-with-advanced-unresectable-biliary-tract-cancer/ 2022-05-26T21:20:14+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/EMA.jpg http://www.pharmajournalist.com/fda-accepts-for-review-biohavens-new-drug-application-nda-filing-of-intranasal-zavegepant-for-the-acute-treatment-of-migraine/ 2022-05-26T21:21:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-for-expanded-use-in-childhood-arthritic-conditions/ 2022-05-26T21:23:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/inceptor-bio-announces-37-million-series-a-financing-to-develop-cell-therapies-for-difficult-to-treat-cancers/ 2022-05-26T21:24:40+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/registration-is-now-open-for-wearable-injectors-and-connected-devices-conference-2022/ 2022-05-31T11:03:51+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/P-384-2022-300x250-.jpg http://www.pharmajournalist.com/sanofi-grants-regeneron-worldwide-exclusive-license-rights-to-libtayo-cemiplimab/ 2022-06-03T11:39:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/moderna-and-the-european-commission-agree-on-amendment-to-covid-19-vaccine-supply-agreement/ 2022-06-03T11:41:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/cocrystal-pharma-expands-collaboration-with-the-national-institute-of-allergy-and-infectious-diseases-to-evaluate-covid-19-protease-inhibitors/ 2022-06-03T11:42:40+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/theolytics-starts-a-1m-project-in-collaboration-with-the-university-of-sheffield-supported-by-innovate-uk-to-develop-a-novel-therapy-for-multiple-myeloma-patients/ 2022-06-03T11:43:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/myovant-sciences-and-pfizer-announce-fda-acceptance-of-supplemental-new-drug-application-for-myfembree/ 2022-06-03T11:45:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/gsk-to-acquire-clinical-stage-biopharmaceutical-company-affinivax-inc/ 2022-06-03T11:51:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/takeda-and-moderna-announce-plans-to-transfer-marketing-authorization-for-spikevaxtm-covid-19-vaccine-in-japan-to-moderna/ 2022-06-03T11:59:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/fda-approves-roches-evrysdi-for-use-in-babies-under-two-months-with-spinal-muscular-atrophy-sma/ 2022-06-03T12:01:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/nrg-therapeutics-announces-2-68m-innovate-uk-award-to-develop-new-medicines-to-treat-parkinsons-and-motor-neuron-disease/ 2022-06-03T12:02:34+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/evotec-adds-cell-therapy-manufacturing-facility-with-acquisition-of-rigenerand/ 2022-06-03T12:04:11+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/fda-approves-novartis-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma/ 2022-06-03T12:05:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/china-approves-cervarix-two-dose-vaccine-schedule-for-girls-aged-9-to-14-against-certain-types-of-cancer-causing-human-papillomavirus/ 2022-06-03T12:07:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/biogen-and-samsung-bioepis-byooviz-ranibizumab-nuna-launches-in-the-united-states/ 2022-06-03T12:09:46+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/agilent-announces-collaboration-with-apc-on-real-time-process-monitoring/ 2022-06-30T18:29:03+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/agilent-logo.png http://www.pharmajournalist.com/sirnaomics-launches-phase-i-clinical-trial-of-rnai-therapeutic-stp705-in-adults-undergoing-abdominoplasty-for-medical-cosmetology-treatment/ 2022-06-03T12:12:00+00:00 https://pharmajournalist.com/wp-content/uploads/2021/04/Sirnaomics_Logo.jpg http://www.pharmajournalist.com/jubilant-hollisterstier-llc-enters-into-cooperative-agreement-of-149-6-mn-with-us-government-to-expand-critical-vaccine-manufacturing-capacity/ 2022-06-03T12:13:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/astellas-and-go-therapeutics-enter-into-strategic-research-and-license-agreement-to-develop-novel-antibodies-for-immuno-oncology/ 2022-06-03T12:14:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/bone-therapeutics-signs-definitive-subscription-agreement-for-a-maximum-of-eur-5m-convertible-bonds-facility-with-abo/ 2022-06-03T12:16:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/cambrex-acquires-leading-eu-stability-storage-company-q1-scientific/ 2022-06-03T12:18:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/cambrex-logo.png http://www.pharmajournalist.com/amneal-launches-lyvispah-baclofen-for-spasticity-related-to-multiple-sclerosis-and-other-spinal-cord-disorders/ 2022-06-03T12:20:39+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/fda-advisory-committee-recommends-emergency-use-authorization-of-novavax-covid-19-vaccine-for-people-aged-18-years-and-older/ 2022-06-09T06:35:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/catalent-and-migvax-sign-agreement-to-develop-an-orally-disintegrating-freeze-dried-tablet-vaccine-against-covid-19/ 2022-06-09T06:36:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/biogen-and-alectos-therapeutics-announce-license-and-collaboration-agreement-for-al01811-a-novel-gba2-inhibitor-for-the-potential-treatment-of-parkinsons-disease/ 2022-06-09T06:37:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/join-our-expert-industry-thought-leaders-who-present-case-studies-and-updates-to-the-industry/ 2022-06-09T11:40:34+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/Pre-Filled-Syringes-San-Fran.jpg http://www.pharmajournalist.com/mineralys-therapeutics-closes-118-million-oversubscribed-series-b-financing-to-advance-the-development-of-novel-targeted-treatment-for-hypertension/ 2022-06-10T09:23:00+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/sinovac-polio-vaccine-prequalified-by-who/ 2022-06-10T09:24:59+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Sinovac-Biotech-Logo.jpg http://www.pharmajournalist.com/integral-molecular-and-optimeos-life-sciences-enter-partnership-to-develop-mrna-and-dna-based-gene-therapies-using-molecular-targeting/ 2022-06-10T09:25:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/nice-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/ 2022-06-17T10:45:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/pierre-fabre-and-lonza-enter-manufacturing-agreement-for-w0180-antibody-drug-product/ 2022-06-17T11:03:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/lonza.jpg http://www.pharmajournalist.com/start-of-rolling-review-for-adapted-comirnaty-covid-19-vaccine/ 2022-06-17T11:05:13+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/EMA.jpg http://www.pharmajournalist.com/jazz-pharmaceuticals-and-redx-announce-pan-raf-inhibitor-jzp815-to-enter-clinical-development/ 2022-06-17T11:06:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/jazz-pharmaceuticals.jpg http://www.pharmajournalist.com/eurocine-vaccines-expands-its-portfolio-with-a-therapeutic-hsv-2-vaccine-candidate/ 2022-06-17T11:08:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/new-research-identifies-more-than-1000-genes-linked-to-severe-covid-19/ 2022-06-17T11:10:52+00:00 https://pharmajournalist.com/wp-content/uploads/2022/06/New-research-COVID-19.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/06/New-research-COVID-19.jpg http://www.pharmajournalist.com/amylyx-pharmaceuticals-announces-health-canada-approval-of-albrioza-for-the-treatment-of-als/ 2022-06-17T11:12:55+00:00 https://pharmajournalist.com/wp-content/uploads/2019/12/Amylyx-Logo.jpg http://www.pharmajournalist.com/china-nmpa-approves-tislelizumab-for-recurrent-or-metastatic-nasopharyngeal-cancer/ 2022-06-17T11:14:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/coave-therapeutics-and-abl-enter-into-strategic-collaboration-to-develop-gene-therapy-manufacturing-processes-and-create-joint-capabilities-for-process-development-of-aav-based-gene-therapy/ 2022-06-17T11:15:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/pfizer-completes-acquisition-of-reviral/ 2022-06-17T11:17:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/everest-medicines-announces-approval-of-trodelvy-in-china-for-second-line-metastatic-triple-negative-breast-cancer/ 2022-06-17T11:22:50+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Everest-Medicines-Logo.jpg http://www.pharmajournalist.com/ferring-announces-new-collaboration-for-development-of-olamkicept/ 2022-06-17T11:24:25+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Ferring-Pharmaceuticals-Singapore.jpg http://www.pharmajournalist.com/oxford-biotherapeutics-announces-research-collaboration-with-immunogen-to-develop-novel-antibody-drug-conjugates/ 2022-06-17T11:25:34+00:00 https://pharmajournalist.com/wp-content/uploads/2018/12/Oxford-Biotherapeutics-Logo.jpg http://www.pharmajournalist.com/pfizer-morphosys-and-incyte-enter-into-clinical-trial-collaboration-for-monjuvi-tafasitamab-cxix-in-combination-with-tti-622-a-fusion-protein-directed-against-cd47/ 2022-06-17T11:27:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/fda-approves-lilly-and-incytes-olumiant-baricitinib-as-first-and-only-systemic-medicine-for-adults-with-severe-alopecia-areata/ 2022-06-17T11:29:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/evotec-enters-a-drug-discovery-collaboration-with-janssen/ 2022-06-17T11:31:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-carthronix-announce-partnership-to-pursue-small-molecule-therapeutics-in-canine-oncology/ 2022-06-17T11:32:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/kintara-therapeutics-granted-fast-track-designation-from-the-fda-for-val-083-for-newly-diagnosed-glioblastoma/ 2022-06-17T11:33:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/exelixis-and-bioinvent-establish-exclusive-option-and-license-agreement-to-develop-novel-antibody-based-immuno-oncology-therapies/ 2022-06-17T11:35:02+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Exelixis.jpg http://www.pharmajournalist.com/panbela-therapeutics-closes-acquisition-of-cancer-prevention-pharmaceuticals/ 2022-06-17T11:36:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/humanigen-enters-into-agreement-with-pci-pharma-services-as-part-of-preparations-for-commercialization-in-the-united-kingdom/ 2022-06-17T11:38:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/you-may-have-missed-the-east-coast-and-san-diego-event-but-join-the-san-francisco-pre-filled-syringe-event-instead/ 2022-06-21T10:00:30+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/Pre-Filled-Syringes-San-Fran.jpg http://www.pharmajournalist.com/novavax-nuvaxovid-covid-19-vaccine-receives-emergency-use-authorization-in-taiwan-for-use-in-individuals-aged-18-and-over/ 2022-06-24T09:57:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/novartis-receives-european-commission-approval-for-tabrecta-for-the-treatment-of-metex14-skipping-advanced-non-small-cell-lung-cancer/ 2022-06-24T09:58:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/ 2022-06-24T10:00:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/biomarins-voxzogo-obtains-japans-mhlw-approval-for-achondroplasia/ 2022-06-24T10:02:54+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Biomarin-Pharma-Logo.jpg http://www.pharmajournalist.com/galapagos-to-acquire-cellpoint-and-aboundbio-to-accelerate-access-to-next-generation-cell-therapies/ 2022-06-24T10:07:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/01/Galapagos-NV-Logo.png http://www.pharmajournalist.com/moderna-announces-plan-to-bring-mrna-innovation-to-the-united-kingdom/ 2022-06-24T10:09:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/new-agreement-paves-way-for-development-of-first-african-owned-covid-19-vaccine/ 2022-06-24T10:10:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/valneva-and-pfizer-announce-closing-of-equity-investment/ 2022-06-24T10:12:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/kinarus-therapeutics-kin001-shows-strong-antiviral-activity-against-sars-cov-2-and-variants-of-concern/ 2022-06-24T10:13:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/jatt-acquisition-corp-and-zura-bio-limited-announce-definitive-business-combination-agreement-to-create-nyse-listed-biotechnology-company/ 2022-06-24T10:18:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sandoz-application-for-proposed-biosimilar-adalimumabs-high-concentration-formulation-accepted-by-ema/ 2022-06-24T10:20:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/waters-and-bioinfra-establish-the-asean-academy-for-bioanalysis-to-promote-analytical-skills-development/ 2022-06-24T10:21:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/johnson-johnson-opens-first-satellite-center-for-global-health-discovery-in-asia-pacific-at-duke-nus-to-advance-dengue-research/ 2022-06-24T10:23:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/truveta-announces-strategic-collaboration-with-pfizer-to-accelerate-safety-insights-in-real-time/ 2022-06-24T10:24:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/ani-pharmaceuticals-announces-fda-approval-and-imminent-launch-of-clorazepate-dipotassium-tablets-usp/ 2022-06-24T10:28:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/echosens-and-novo-nordisk-announce-partnership-to-increase-awareness-and-advance-early-diagnosis-of-nash/ 2022-06-24T10:36:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/radius-health-announces-agreement-to-be-acquired-by-gurnet-point-capital-and-patient-square-capital/ 2022-06-24T10:38:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/merck-opens-e59-million-cdmo-facility-to-address-demand-for-critical-cancer-therapies/ 2022-06-24T10:39:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/novartis-tafinlar-mekinist-receives-fda-approval-for-first-tumor-agnostic-indication-for-braf-v600e-solid-tumors/ 2022-06-24T10:41:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/ellipses-announces-fda-clearance-of-ind-application-for-ep0031-for-patients-with-advanced-ret-altered-malignancies/ 2022-06-24T10:44:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/vbi-vaccines-receives-u-s-fda-orphan-drug-designation-for-vbi-1901-for-the-treatment-of-glioblastoma/ 2022-06-24T10:45:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/VBI-Vaccines-Logo.jpg http://www.pharmajournalist.com/next-generation-pharmaceutical-cleanrooms-conference-is-back-in-october-2022-speakers-and-agenda-released/ 2022-06-30T10:30:16+00:00 https://pharmajournalist.com/wp-content/uploads/2022/06/P-383-Pharmaceutical-Cleanroom-2022-300x250-copy.jpg http://www.pharmajournalist.com/pfizer-and-biontech-announce-new-agreement-with-u-s-government-to-provide-additional-doses-of-covid-19-vaccine/ 2022-06-30T10:49:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/japans-ministry-of-health-labour-and-welfare-accepts-shingrix-regulatory-submission-to-prevent-shingles-in-at-risk-adults-aged-18-years-and-older/ 2022-06-30T10:50:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/kites-car-t-cell-therapy-yescarta-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma/ 2022-06-30T10:51:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/terumo-blood-and-cell-technologies-and-gencure-collaborate-to-advance-cell-and-gene-therapy-manufacturing-solutions/ 2022-06-30T10:53:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-roches-lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma/ 2022-07-08T07:42:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/pfizer-announces-submission-of-new-drug-application-to-the-u-s-fda-for-paxlovid/ 2022-07-08T07:47:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/brii-biosciences-announces-commercial-launch-of-its-amubarvimab-romlusevimab-combination-therapy-for-covid-19-in-china/ 2022-07-08T07:48:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/curevac-files-patent-infringement-lawsuit-in-germany-against-biontech/ 2022-07-08T07:50:23+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/Curevac-logo.png http://www.pharmajournalist.com/novavax-nuvaxovid-covid-19-vaccine-conditionally-authorized-in-the-european-union-for-adolescents-aged-12-through-17/ 2022-07-08T07:52:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/astrazeneca-to-acquire-teneotwo-and-its-clinical-stage-t-cell-engager-strengthening-haematological-cancer-pipeline/ 2022-07-08T07:53:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/sanofi-global-health-launches-nonprofit-impact-brand-for-30-medicines-in-low-income-countries/ 2022-07-08T07:54:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/brii-biosciences-exercises-option-for-vir-biotechnologys-vir-3434-a-broadly-neutralizing-monoclonal-antibody-targeting-hepatitis-b-in-greater-china/ 2022-07-08T07:56:15+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gsk-completes-acquisition-of-sierra-oncology/ 2022-07-08T07:58:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/oxford-biomedica-signs-new-three-year-agreement-with-astrazeneca/ 2022-07-08T08:00:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/oxford-biomedica.jpg http://www.pharmajournalist.com/blueprint-medicines-announces-transformative-1-25-billion-strategic-financing-collaborations-with-sixth-street-and-royalty-pharma/ 2022-07-08T08:02:07+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/twist-bioscience-and-ildong-pharmaceutical-enter-into-a-collaboration-to-enhance-antibody-discovery-for-applications-in-immuno-oncology/ 2022-07-08T08:03:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Twist-Bioscience-logo.jpg http://www.pharmajournalist.com/phanes-therapeutics-pt886-granted-orphan-drug-designation-for-the-treatment-of-pancreatic-cancer-by-the-fda/ 2022-07-08T08:05:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/vaxart-announces-agreement-with-hvivo-to-develop-worlds-first-human-omicron-challenge-model/ 2022-07-08T08:06:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lonza-to-establish-large-scale-commercial-drug-product-fill-finish-facility-in-stein-ch/ 2022-07-08T08:08:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/Lonza.jpg http://www.pharmajournalist.com/proteonic-announces-licensing-of-its-premium-2g-unic-technology-platform-for-production-of-biologics-to-fyonibio/ 2022-07-08T08:09:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/evotec-completes-acquisition-of-rigenerand/ 2022-07-08T08:10:57+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies/ 2022-07-08T08:12:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/exelixis-and-ryvu-therapeutics-establish-exclusive-license-agreement-to-develop-novel-sting-agonist-based-targeted-cancer-therapies/ 2022-07-08T08:18:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Exelixis.jpg http://www.pharmajournalist.com/turnstone-biologics-and-moffitt-cancer-center-announce-strategic-alliance-to-advance-next-generation-til-therapies-for-solid-tumors/ 2022-07-08T08:19:52+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/mogrify-and-astellas-announce-collaboration-to-conduct-research-on-in-vivo-regenerative-medicine-approaches-to-address-sensorineural-hearing-loss/ 2022-07-08T08:22:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/network-with-johnson-johnson-springboard-bsi-astrazeneca-and-many-more-at-the-wearable-injectors-connected-devices-conference/ 2022-07-08T09:19:57+00:00 https://pharmajournalist.com/wp-content/uploads/2022/07/P-384-2022-650-x-650-.jpg https://pharmajournalist.com/wp-content/uploads/2022/07/P-384-2022-650-x-650-.jpg http://www.pharmajournalist.com/fda-releases-draft-guidance-on-cmc-for-individualized-aso-therapies/ 2022-07-11T08:06:04+00:00 https://pharmajournalist.com/wp-content/uploads/2022/07/P-382-Oligo-2022-650-x-650-copy-1.jpg https://pharmajournalist.com/wp-content/uploads/2022/07/P-382-Oligo-2022-650-x-650-copy-1.jpg http://www.pharmajournalist.com/brochure-available-for-biosensors-for-medical-wearables-conference-2022/ 2022-07-12T09:53:39+00:00 https://pharmajournalist.com/wp-content/uploads/2022/07/TP-002-2022-650x650-.jpg https://pharmajournalist.com/wp-content/uploads/2022/07/TP-002-2022-650x650-.jpg http://www.pharmajournalist.com/health-canada-authorizes-use-of-moderna-covid-19-vaccine-in-children-6-months-to-5-years-of-age/ 2022-07-15T09:32:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/health-canada-logo.jpg http://www.pharmajournalist.com/fda-grants-emergency-use-authorization-for-novavax-covid-19-vaccine-adjuvanted-for-individuals-aged-18-and-over/ 2022-07-15T09:36:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/avrobio-receives-orphan-drug-designation-from-the-fda-for-avr-rd-05-a-gene-therapy-for-mucopolysaccharidosis-type-ii-mpsii-or-hunter-syndrome/ 2022-07-15T09:44:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/Avrobio-Logo.jpg http://www.pharmajournalist.com/innoviva-sells-15-economic-stake-in-theravance-respiratory-company-to-royalty-pharma-for-approximately-282-million-plus-full-ownership-of-existing-equity-investments-and-the-potential-for-50-million/ 2022-07-15T09:45:49+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/orion-and-msd-announce-global-collaboration-for-the-development-and-commercialisation-of-odm-208-an-investigational-steroid-synthesis-inhibitor-for-the-treatment-of-metastatic-castration-resistant-pr/ 2022-07-15T09:47:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/bicycle-therapeutics-announces-further-expansion-of-genentech-immuno-oncology-collaboration/ 2022-07-15T09:51:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/Bicycle-Therapeutics.jpg http://www.pharmajournalist.com/genscript-probio-signs-mou-to-form-strategic-partnership-with-act-therapeutics-to-development-of-new-car-t-cell-therapies/ 2022-07-15T09:52:30+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/GenScript.jpg http://www.pharmajournalist.com/arcutis-biotherapeutics-announces-health-canada-accepts-for-review-the-new-drug-submission-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/ 2022-07-15T09:54:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/vertex-to-acquire-viacyte-with-the-goal-of-accelerating-its-potentially-curative-vx-880-programs-in-type-1-diabetes/ 2022-07-15T10:49:00+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/innoviva-to-acquire-la-jolla-pharmaceutical-company/ 2022-07-15T10:50:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-krystexxa-pegloticase-injection-co-administered-with-methotrexate-expanding-the-labeling-to-help-more-people-with-uncontrolled-gout-achieve-a-complete-response-to-therapy/ 2022-07-15T10:54:21+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/Horizon-Therapeutics-Logo.jpg http://www.pharmajournalist.com/pfizer-and-biontech-announce-fda-approval-of-their-covid-19-vaccine-comirnaty-for-adolescents-12-through-15-years-of-age/ 2022-07-15T10:55:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/adc-therapeutics-announces-exclusive-license-agreement-with-sobi-to-develop-and-commercialize-zynlonta-loncastuximab-tesirine-lpyl-in-europe-and-select-international-territories/ 2022-07-15T11:03:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/ADC_Therapeutics_Logo.png http://www.pharmajournalist.com/zymergen-expands-agreement-with-octant-to-scale-next-generation-drug-discovery-platform/ 2022-07-15T11:06:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/codexis-announces-agreement-with-pfizer-to-supply-enzyme-for-the-manufacture-of-paxlovid-nirmatrelvir-tablets-ritonavir-tablets/ 2022-07-15T11:08:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/dnanexus-and-twist-bioscience-collaborate-to-provide-data-analysis-software-for-ngs-workflow/ 2022-07-15T11:10:07+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/DNAnexus-logo.png http://www.pharmajournalist.com/labcorp-launches-new-test-to-identify-and-confirm-neurodegenerative-disease/ 2022-07-15T11:11:46+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/LabCorp.jpg http://www.pharmajournalist.com/discovery-life-sciences-acquires-allcells/ 2022-07-15T11:13:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/solvias-acquires-cergentis-to-bolster-biologics-and-cell-gene-therapy-capabilities/ 2022-07-15T11:14:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-launches-ce-ivd-marked-taqpath-respiratory-viral-select-panel/ 2022-07-15T11:15:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/anthos-therapeutics-announces-that-abelacimab-has-received-fda-fast-track-designation-for-the-treatment-of-thrombosis-associated-with-cancer/ 2022-07-15T11:16:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/sk-biopharmaceuticals-eurofarma-enter-into-licensing-agreement-for-cenobamate-in-latin-america/ 2022-07-15T11:18:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-odd-status-to-neoimmunetechs-nt-i7-for-the-treatment-of-glioblastoma-multiforme/ 2022-07-15T11:19:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/inspirna-raises-50-million-in-series-d-financing/ 2022-07-15T11:20:08+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/wuxi-xdc-and-abtis-sign-memorandum-of-understanding-for-development-and-manufacturing-of-antibody-drug-conjugates/ 2022-07-15T11:21:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/registration-is-now-open-for-the-5th-annual-ophthalmic-drugs-conference/ 2022-07-15T13:20:05+00:00 https://pharmajournalist.com/wp-content/uploads/2022/07/P-386-OD-650x650-.jpg https://pharmajournalist.com/wp-content/uploads/2022/07/P-386-OD-650x650-.jpg http://www.pharmajournalist.com/expert-speakers-will-discuss-the-cmc-approaches-to-injectable-device-development-on-the-3rd-annual-pre-filled-syringes-san-francisco-conference-2022/ 2022-07-21T08:08:01+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/Pre-Filled-Syringes-San-Fran.jpg http://www.pharmajournalist.com/european-commission-approves-purchase-agreement-amendment-for-valnevas-inactivated-covid-19-vaccine/ 2022-07-22T09:39:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/zyversa-therapeutics-to-become-a-publicly-traded-biopharma-company-via-merger-with-larkspur-health-acquisition-corp/ 2022-07-22T09:47:49+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/Zyversa-Logo.jpg http://www.pharmajournalist.com/karyopharm-granted-regulatory-designations-for-eltanexor-for-the-treatment-of-myelodysplastic-syndromes/ 2022-07-22T09:52:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/karyopharma-logo.png http://www.pharmajournalist.com/treatment-of-covid-19-in-switzerland-astrazeneca-delivers-antibody-therapies/ 2022-07-22T10:00:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/ 2022-07-22T10:06:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/incyte-announces-fda-approval-of-opzelura-ruxolitinib-cream-for-the-treatment-of-vitiligo/ 2022-07-22T11:27:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/incyte-logo.jpg http://www.pharmajournalist.com/abbvie-submits-marketing-authorization-application-to-ema-for-atogepant-for-the-preventive-treatment-of-migraine/ 2022-07-22T11:29:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/abbvie.jpg http://www.pharmajournalist.com/therapeutic-goods-administration-grants-provisional-approval-for-modernas-covid-19-vaccine-in-children-aged-six-months-to-five-years/ 2022-07-22T11:30:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/endo-announces-agreement-for-paladin-labs-to-develop-commercialize-and-supply-quoin-pharmaceuticals-qrx003-in-canada/ 2022-07-22T11:32:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/everest-medicines-announces-european-commission-grants-approval-of-kinpeygo-for-adults-with-primary-iga-nephropathy-to-our-partner-calliditas-therapeutics/ 2022-07-22T11:35:01+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Everest-Medicines-Logo.jpg http://www.pharmajournalist.com/azurity-pharmaceuticals-inc-announces-fda-approval-of-zonisade-zonisamide-oral-suspension/ 2022-07-22T11:55:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/nabriva-therapeutics-expands-xenleta-lefamulin-presence-with-exclusive-agreement-with-er-kim-pharmaceuticals/ 2022-07-22T11:57:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sorrento-therapeutics-announces-the-fda-ind-clearance-of-sti-1558-an-oral-mpro-and-cathepsin-l-inhibitor-to-treat-covid-19/ 2022-07-22T11:58:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/sorrento-therapeutics.jpg http://www.pharmajournalist.com/gilead-sciences-signs-new-joint-procurement-agreement-with-the-european-commission-for-veklury-remdesivir/ 2022-07-22T11:59:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/biocytogen-and-liberothera-achieve-milestone-progress-in-co-development-of-fully-human-gpcr-antibody-drugs/ 2022-07-22T12:02:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/daewoong-pharmaceutical-gets-first-korean-us-fda-fast-track-for-new-idiopathic-pulmonary-fibrosis-drug/ 2022-07-22T12:04:59+00:00 https://pharmajournalist.com/wp-content/uploads/2022/07/1.jpg https://pharmajournalist.com/wp-content/uploads/2022/07/1.jpg http://www.pharmajournalist.com/scientific-innovation-and-collaboration-highlighted-at-aids-2022-as-gilead-extends-leadership-efforts-toward-ending-the-global-hiv-epidemic/ 2022-07-22T12:06:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gilead.jpg http://www.pharmajournalist.com/artizan-biosciences-announces-multi-year-research-collaboration-with-the-university-medical-center-utrecht-and-microviable-therapeutics-sl/ 2022-07-22T12:07:25+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/camp4-secures-100-million-series-b-financing-to-accelerate-expansion-of-its-novel-regulatory-rna-targeting-platform-and-advance-lead-programs-into-the-clinic/ 2022-07-22T12:09:12+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/amylyx-pharmaceuticals-announces-partnership-agreement-with-sunnybrook-research-institute-to-identify-novel-drug-candidates-for-neurodegenerative-diseases/ 2022-07-22T12:10:23+00:00 https://pharmajournalist.com/wp-content/uploads/2019/12/Amylyx-Logo.jpg http://www.pharmajournalist.com/novartis-and-uc-berkeley-extend-alliance-to-tackle-undruggable-disease-targets-and-discover-new-therapeutic-modalities/ 2022-07-29T10:31:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/melinta-therapeutics-and-cidara-therapeutics-announce-licensing-agreement-to-commercialize-rezafungin-in-the-u-s/ 2022-07-29T10:33:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ionis-announces-that-fda-accepts-new-drug-application-and-grants-priority-review-of-tofersen-for-a-rare-genetic-form-of-als/ 2022-07-29T10:34:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/ionis-pharma1.jpg http://www.pharmajournalist.com/european-commission-approves-rinvoq-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-ulcerative-colitis/ 2022-07-29T10:35:37+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/novavax-announces-expanded-approval-of-nuvaxovid-covid-19-vaccine-for-adolescents-aged-12-through-17-in-japan/ 2022-07-29T10:37:13+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/newamsterdam-pharma-holding-b-v-and-frazier-lifesciences-acquisition-corporation-announce-merger-agreement-to-create-publicly-listed-company-focused-on-transformative-oral-therapies-for-major-cardiom/ 2022-07-29T10:39:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ginkgo-to-acquire-zymergen/ 2022-07-29T10:41:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/applications-for-proposed-first-of-a-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-by-us-fda-and-ema/ 2022-07-29T10:42:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/bavarian-nordic-receives-european-approval-of-extension-of-vaccine-label-to-include-monkeypox/ 2022-07-29T10:43:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/enhertu-granted-priority-review-in-the-us-for-patients-with-her2-low-metastatic-breast-cancer/ 2022-07-29T10:45:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/european-orphan-medicinal-product-designation-granted-to-sangamo-therapeutics-investigational-car-treg-cell-therapy-tx200-for-solid-organ-transplantation/ 2022-07-29T10:46:27+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/Sangamo-Therapeutics.jpg http://www.pharmajournalist.com/new-sponsors-announced-for-pre-filled-syringes-san-francisco-2022-this-september/ 2022-08-03T09:55:04+00:00 https://pharmajournalist.com/wp-content/uploads/2022/05/Pre-Filled-Syringes-San-Fran.jpg http://www.pharmajournalist.com/speaker-interview-with-macarena-hernandez-jimenez-released-for-oligonucleotide-therapeutics-delivery-conference-2022/ 2022-08-04T09:56:17+00:00 https://pharmajournalist.com/wp-content/uploads/2022/04/P-382-Oligo-2022-300x250-PJ-.jpg http://www.pharmajournalist.com/gilead-sciences-to-acquire-mirobio/ 2022-08-05T10:12:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/poseida-therapeutics-announces-strategic-global-collaboration-with-roche-focused-on-allogeneic-car-t-cell-therapies-for-hematologic-malignancies/ 2022-08-05T10:14:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/sinovac-covid-19-vaccine-approved-for-use-in-children-above-6-months-of-age-in-hong-kong/ 2022-08-05T10:15:49+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Sinovac-Biotech-Logo.jpg http://www.pharmajournalist.com/rigel-pharmaceuticals-and-forma-therapeutics-announce-licensing-agreement-for-olutasidenib/ 2022-08-05T10:25:52+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Rigel-Pharma-Logo.png http://www.pharmajournalist.com/sosei-heptares-and-abbvie-enter-new-multi-target-collaboration-to-discover-develop-and-commercialize-novel-medicines-targeting-neurological-diseases/ 2022-08-05T10:43:37+00:00 https://pharmajournalist.com/wp-content/uploads/2019/08/Sosei_Logo.png http://www.pharmajournalist.com/stelara-ustekinumab-approved-by-the-food-and-drug-administration-to-treat-pediatric-patients-with-active-psoriatic-arthritis/ 2022-08-05T10:47:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Janssen-Pharma-Logo.jpg http://www.pharmajournalist.com/greenlight-biosciences-and-samsung-biologics-complete-first-commercial-scale-engineering-run-for-mrna-covid-19-vaccine/ 2022-08-05T10:49:00+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/Samsung-BioLogics.jpg http://www.pharmajournalist.com/nih-greenlight-biosciences-to-collaborate-on-covid-19-vaccine-development-for-new-variants/ 2022-08-05T10:50:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/innovent-biologics-and-sanofi-enter-strategic-collaboration-to-accelerate-development-of-oncology-medicines-and-expand-presence-in-china/ 2022-08-05T10:52:55+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/radiopharm-enters-into-strategic-collaboration-with-lantheus-and-assumes-pd-l1-licensing-agreement-from-nanomab/ 2022-08-05T10:56:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/twist-bioscience-and-biotia-receive-expanded-emergency-use-authorization-to-report-genetic-variants-of-sars-cov-2/ 2022-08-05T10:57:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Twist-Bioscience-logo.jpg http://www.pharmajournalist.com/synthego-launches-engineered-cell-libraries-to-validate-targets-with-speed-and-accelerate-drug-discovery/ 2022-08-05T10:59:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/krystal-biotech-announces-fda-acceptance-of-kb407-ind-application-for-cystic-fibrosis-clinical-trial/ 2022-08-05T11:00:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/xeris-commercialization-partner-for-ogluo-tetris-pharma-ltd-to-be-acquired-by-arecor-therapeutics/ 2022-08-05T11:01:45+00:00 https://pharmajournalist.com/wp-content/uploads/2019/03/Xeris-Logo.jpg http://www.pharmajournalist.com/acadia-pharmaceuticals-receives-complete-response-letter-from-u-s-fda-for-supplemental-new-drug-application-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-alzheime/ 2022-08-05T11:06:17+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/ACADIA-Pharma-Logo.jpg http://www.pharmajournalist.com/kiniksa-pharmaceuticals-announces-global-license-agreement-with-genentech-for-vixarelimab/ 2022-08-05T11:11:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/transcode-therapeutics-and-md-anderson-announce-strategic-alliance-to-advance-rna-therapies-for-oncology/ 2022-08-05T11:12:12+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gamida-cell-announces-fda-acceptance-of-biologics-license-application-for-omidubicel-with-priority-review/ 2022-08-05T11:13:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/new-speaker-interview-released-with-geraint-davies-for-wearable-injectors-connected-devices-conference/ 2022-08-05T12:07:59+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/P-384-Geraint-Davies-.jpg https://pharmajournalist.com/wp-content/uploads/2022/08/P-384-Geraint-Davies-.jpg http://www.pharmajournalist.com/enhertu-approved-in-the-us-as-the-first-her2-directed-therapy-for-patients-with-previously-treated-her2-mutant-metastatic-non-small-cell-lung-cancer/ 2022-08-12T12:18:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/ceapro-inc-expands-collaborative-research-program-with-mcmaster-university-to-develop-an-inhalable-immuno-therapeutic-prophylactic-for-covid-19-induced-lung-fibrosis/ 2022-08-12T12:20:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gentibio-announces-collaboration-with-bristol-myers-squibb-to-pioneer-engineered-treg-therapies-for-inflammatory-bowel-diseases/ 2022-08-12T12:21:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/aro-biotherapeutics-receives-fda-orphan-drug-designation-for-abx1100-for-the-treatment-of-pompe-disease/ 2022-08-12T12:22:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/respiratory-monitoring-ai-technologies-hear-more-at-the-biosensors-for-medical-wearables-conference/ 2022-08-16T21:45:48+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/TP-002-Pierre-Alexandre-Fournier-.jpg https://pharmajournalist.com/wp-content/uploads/2022/08/TP-002-Pierre-Alexandre-Fournier-.jpg http://www.pharmajournalist.com/key-presentations-at-the-medical-devices-ivd-conference-released/ 2022-08-17T23:25:43+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/P-385-Medical-Devices-2022-650x650-.jpg https://pharmajournalist.com/wp-content/uploads/2022/08/P-385-Medical-Devices-2022-650x650-.jpg http://www.pharmajournalist.com/european-commission-approves-celltrion-healthcares-vegzelma-ct-p16-biosimilar-bevacizumab-for-the-treatment-of-multiple-types-of-cancer/ 2022-08-19T12:16:16+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/celltrion-Image.png http://www.pharmajournalist.com/bluebird-bio-announces-fda-approval-of-zynteglo-the-first-gene-therapy-for-people-with-beta-thalassemia-who-require-regular-red-blood-cell-transfusions/ 2022-08-19T12:17:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/bluebird-bio-inc.jpg http://www.pharmajournalist.com/atomwise-signs-strategic-multi-target-research-collaboration-with-sanofi-for-ai-powered-drug-discovery/ 2022-08-19T12:22:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/novavax-nuvaxovid-covid-19-vaccine-granted-expanded-provisional-approval-in-new-zealand-as-a-first-and-second-booster-for-adults/ 2022-08-19T12:23:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/fda-accepts-supplemental-biologics-license-application-for-roches-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma/ 2022-08-19T12:24:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/roosterbio-and-agc-biologics-announce-collaboration-to-accelerate-manufacturing-of-cell-and-exosome-therapies/ 2022-08-19T12:26:03+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/merck-and-orna-therapeutics-collaborate-to-advance-ornas-next-generation-of-rna-technology/ 2022-08-19T12:27:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/valneva-initiates-rolling-submission-of-fda-biologics-license-application-for-its-single-shot-chikungunya-vaccine-candidate/ 2022-08-19T12:29:05+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/gilead-to-acquire-remaining-worldwide-rights-of-trodelvy/ 2022-08-19T12:30:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/nuance-pharma-announces-clearance-of-ind-application-for-ensifentrine-pivotal-clinical-trials-for-copd-in-china/ 2022-08-19T12:32:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/fda-accepts-astellas-new-drug-application-for-fezolinetant/ 2022-08-19T12:33:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/bristol-myers-squibb-completes-acquisition-of-turning-point-therapeutics-expanding-precision-oncology-portfolio/ 2022-08-19T12:34:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/wuxi-sta-breaks-ground-for-new-pharmaceutical-manufacturing-facility-in-middletown-delaware/ 2022-08-19T12:36:46+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/Photo1-Wuxi.jpg https://pharmajournalist.com/wp-content/uploads/2022/08/Photo1-Wuxi.jpg http://www.pharmajournalist.com/mitsubishi-tanabe-pharma-america-announces-real-world-data-analysis-of-survival-with-radicava-edaravone/ 2022-08-19T12:39:28+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/Mitsubishi-Tanabe-Logo.jpg http://www.pharmajournalist.com/bridge-biotherapeutics-receives-fda-authorization-to-proceed-with-phase-2-study-of-bbt-877/ 2022-08-19T12:40:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/tron-group-inc-and-nanopharmaceutics-inc-announce-definitive-merger-agreement/ 2022-08-19T12:42:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/atyr-pharma-receives-fda-fast-track-designation-for-efzofitimod-atyr1923-for-treatment-of-pulmonary-sarcoidosis/ 2022-08-19T12:43:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/evotec-biologics-and-alpine-immune-sciences-expand-partnership-for-commercial-process-development-of-alpn-303/ 2022-08-19T12:44:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity/ 2022-08-19T12:46:25+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/Catalent-Logo.png http://www.pharmajournalist.com/invitation-from-the-aseptic-processing-conference-chairman-james-drinkwater-at-f-ziel/ 2022-08-22T12:21:50+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/P-381-Aseptic-Processing-2022-1200x627-Chair-banner-James-Drinkwater-copy.jpg https://pharmajournalist.com/wp-content/uploads/2022/08/P-381-Aseptic-Processing-2022-1200x627-Chair-banner-James-Drinkwater-copy.jpg http://www.pharmajournalist.com/developments-in-gene-therapy-for-ocular-diseases/ 2022-08-25T10:53:32+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/P-386-OD.jpg https://pharmajournalist.com/wp-content/uploads/2022/08/P-386-OD.jpg http://www.pharmajournalist.com/elevatebio-and-the-university-of-pittsburgh-announce-creation-of-pitt-bioforge-biomanufacturing-center-at-hazelwood-green-to-accelerate-cell-and-gene-therapy-innovation/ 2022-08-26T12:19:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/novartis-announces-intention-to-separate-sandoz-business-to-create-a-standalone-company-by-way-of-a-100-spin-off/ 2022-08-26T12:21:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/sonoma-biotherapeutics-enters-long-term-lease-agreement-to-establish-a-treg-cell-therapy-rd-and-manufacturing-center/ 2022-08-26T12:23:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/first-gene-therapy-for-adults-with-severe-hemophilia-a-biomarins-roctavian-valoctocogene-roxaparvovec-approved-by-ec/ 2022-08-26T12:26:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Biomarin-Pharma-Logo.jpg http://www.pharmajournalist.com/fda-approves-imbruvica-ibrutinib-as-first-and-only-btki-treatment-for-pediatric-patients-with-chronic-graft-versus-host-disease/ 2022-08-26T12:28:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/lacerta-and-prevail-sign-agreement-to-develop-novel-aav-capsids-for-cns-disorders/ 2022-08-26T12:29:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/iecure-receives-fda-rare-pediatric-disease-designation-for-gtp-506-an-investigational-gene-editing-product-candidate-for-the-treatment-of-ornithine-transcarbamylase-otc-deficiency/ 2022-08-26T12:30:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ocelot-bio-receives-fda-orphan-drug-designation-for-oce-205-for-the-treatment-of-hepatorenal-syndrome/ 2022-08-26T12:33:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/gilead-announces-first-global-regulatory-approval-of-sunlenca-lenacapavir-the-only-twice-yearly-hiv-treatment-option/ 2022-08-26T12:34:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/pfizer-and-biontech-submit-application-to-fda-for-emergency-use-authorization-of-omicron-ba-4-ba-5-adapted-bivalent-covid-19-vaccine/ 2022-08-26T12:36:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/porton-advanced-solutions-completes-a-series-b-financing-round-to-expand-its-end-to-end-gene-and-cell-therapy-cdmo-platforms/ 2022-08-26T12:37:46+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/thermo-fisher-scientifics-largest-single-use-technology-manufacturing-site-opens-in-greater-nashville/ 2022-08-26T12:39:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/alcon-to-acquire-aerie-pharmaceuticals-inc-enhancing-its-ophthalmic-pharmaceutical-portfolio/ 2022-08-26T12:41:42+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/zerion-pharma-and-hovione-extend-partnership-to-cover-use-of-the-dispersome-technology-platform-in-nutraceuticals/ 2022-08-26T12:44:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/windtree-therapeutics-announces-kl4-surfactant-and-aerosurf-global-license-agreement/ 2022-08-26T12:46:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/thermo-fisher-scientific-expands-viral-vector-manufacturing-capabilities/ 2022-08-26T12:47:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/sonde-health-inks-multi-year-partnership-with-koye-pharmaceuticals/ 2022-08-26T12:48:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/aclaris-therapeutics-announces-patent-license-agreement-with-lilly-for-alopecia-areata/ 2022-08-26T12:50:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/bota-bio-and-medichem-announce-commercial-development-collaboration-to-advance-sustainable-pharmaceutical-manufacturing/ 2022-08-26T12:52:50+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/Bota_Bio_Logo.jpg http://www.pharmajournalist.com/10-great-reasons-to-join-the-next-generation-pharmaceutical-cleanrooms-conference/ 2022-08-30T07:47:24+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/P-383-Pharmaceutical-Cleanroom-2022-EB3.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/08/P-383-Pharmaceutical-Cleanroom-2022-EB3.jpg http://www.pharmajournalist.com/novo-nordisk-to-acquire-forma-therapeutics-and-expand-presence-in-sickle-cell-disease-and-rare-blood-disorders/ 2022-09-02T12:40:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/novavax-nuvaxovid-covid-19-vaccine-recommended-by-chmp-for-expanded-conditional-marketing-authorization-in-the-european-union-as-a-booster-for-adults-aged-18-and-older/ 2022-09-02T12:49:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/maze-therapeutics-announces-fda-orphan-drug-designation-granted-to-mze001-for-the-treatment-of-pompe-disease/ 2022-09-02T12:50:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/guardant-health-expands-strategic-collaboration-with-merck-kgaa-darmstadt-germany-to-help-accelerate-development-of-precision-oncology-therapeutics/ 2022-09-02T12:53:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/merck-group.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-efanesoctocog-alfa-for-people-with-hemophilia-a/ 2022-09-02T12:55:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/zerion-pharma-and-insud-pharma-announce-collaboration-to-develop-dispersome-formulations-of-marketed-drug-products/ 2022-09-02T12:57:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sanyou-biopharmaceuticals-and-kangabio-established-strategic-collaboration-to-accelerate-antibody-drug-development-and-innovation/ 2022-09-02T12:59:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/incyte-announces-fda-approval-of-pemazyre-pemigatinib-as-the-first-and-only-targeted-treatment-for-myeloid-lymphoid-neoplasms-mlns-with-fgfr1-rearrangement/ 2022-09-02T13:02:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/incyte-logo.jpg http://www.pharmajournalist.com/moderna-sues-pfizer-and-biontech-for-infringing-patents-central-to-modernas-innovative-mrna-technology-platform/ 2022-09-29T13:02:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/gicell-announces-research-collaboration-with-hk-inno-n-for-next-generation-car-nk-therapy/ 2022-09-02T13:06:57+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/proofpilot-announces-partnership-with-human-api-to-advance-patient-screening-and-clinical-monitoring-in-research/ 2022-09-02T13:08:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/spatial-biology-cro-flagship-biosciences-acquires-pharma-services-business-from-interpace-biosciences/ 2022-09-02T13:10:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/cambrex-completes-first-phase-of-30-million-capacity-expansion-project-in-high-point-north-carolina/ 2022-09-02T13:11:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/cambrex.jpeg http://www.pharmajournalist.com/fda-approves-the-first-treatment-option-for-generalized-pustular-psoriasis-flares-in-adults/ 2022-09-02T13:13:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/amneal-announces-submission-of-new-drug-application-to-the-u-s-fda-for-ipx203-for-the-treatment-of-parkinsons-disease/ 2022-09-02T13:14:37+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/okyo-pharma-plans-q4-2022-ind-filing-of-ok-101-to-treat-dry-eye-disease-with-subsequent-phase-2-initiation-alongside-peptide-manufacturing-partner-ambiopharm/ 2022-09-02T13:16:03+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/Young-boy-has-eye-examination.jpg http://www.pharmajournalist.com/novartis-scemblix-with-novel-mechanism-of-action-approved-by-the-european-commission-for-adult-patients-with-chronic-myeloid-leukemia/ 2022-09-02T13:17:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis/ 2022-09-02T13:19:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/key-topics-not-to-miss-at-the-wearable-injectors-and-connected-devices-conference/ 2022-09-02T13:27:16+00:00 https://pharmajournalist.com/wp-content/uploads/2022/06/P-384-Wearables-email-header.jpg http://www.pharmajournalist.com/gatehouse-bio-extends-its-partnership-with-astrazeneca-to-develop-rna-therapeutics-for-heart-failure/ 2022-09-09T11:29:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/anthos-therapeutics-announces-that-abelacimab-has-received-fda-fast-track-designation-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation/ 2022-09-09T11:30:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/acelink-therapeutics-receives-orphan-drug-designation-for-its-novel-gcs-inhibitor-al01211-for-the-treatment-of-fabry-disease/ 2022-09-09T11:31:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/good-therapeutics-announces-acquisition-of-conditionally-active-pd-1-regulated-il-2-program-by-roche/ 2022-09-09T11:33:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/kites-car-t-cell-therapy-tecartus-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia-r-r-all/ 2022-09-09T11:34:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/tetra-collaborates-with-cellvera-to-develop-a-potential-oral-combination-treatment-for-covid-19-patients/ 2022-09-09T11:35:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/innocare-announces-priority-review-of-orelabrutinib-for-the-treatment-of-r-r-mzl-by-nmpa/ 2022-09-09T11:37:16+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/Innocare-Logo.png http://www.pharmajournalist.com/ava6000-receives-orphan-drug-designation-from-the-us-food-and-drug-administration/ 2022-09-09T11:38:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/imfinzi-plus-chemotherapy-approved-in-the-us-as-the-first-immunotherapy-regimen-for-patients-with-advanced-biliary-tract-cancer/ 2022-09-09T11:39:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/vertex-announces-fda-approval-for-orkambi-lumacaftor-ivacaftor-in-children-with-cystic-fibrosis-ages-12-to/ 2022-09-09T11:41:19+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/azurity-pharmaceuticals-inc-announces-fda-approval-of-konvomep-omeprazole-and-sodium-bicarbonate-for-oral-suspension/ 2022-09-09T11:43:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/advanco-and-vantage-partner-to-offer-first-interoperable-pharma-traceability-solution/ 2022-09-09T11:45:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/citeline-connect-and-proofpilot-announce-strategic-partnership/ 2022-09-09T11:46:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/nanotics-to-collaborate-with-mass-general-cancer-center-mgcc-on-novel-nanomedicine-for-treating-cancer/ 2022-09-09T11:56:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ixlayer-partners-with-curavit-to-enable-convenient-patient-medical-testing-services-for-decentralized-clinical-trials/ 2022-09-09T11:58:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/carsgen-releases-the-first-clinical-batch-of-car-t-cells-from-its-rtp-gmp-manufacturing-facility-in-north-carolina/ 2022-09-09T11:59:15+00:00 https://pharmajournalist.com/wp-content/uploads/2019/11/Carsgen-Therapeutics-Logo.jpg http://www.pharmajournalist.com/bertis-announces-proteomic-based-research-results-of-new-biomarker-for-ovarian-cancer-diagnosis/ 2022-09-09T12:01:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-grants-breakthrough-therapy-designation-to-pfizers-group-b-streptococcus-vaccine-candidate-to-help-prevent-infection-in-infants-via-immunization-of-pregnant-women/ 2022-09-09T12:02:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/evaxion-announces-nih-grant-for-research-collaboration-with-umass-chan-medical-school/ 2022-09-09T12:04:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/forxiga-approved-in-china-for-the-treatment-of-chronic-kidney-disease-in-patients-at-risk-of-progression-with-and-without-type-2-diabetes/ 2022-09-09T12:05:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/fda-approves-the-first-treatment-option-for-generalized-pustular-psoriasis-flares-in-adults-2/ 2022-09-09T12:06:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/who-expands-recommendation-for-veklury-remdesivir-to-patients-with-severe-disease-in-latest-update-to-covid-19-guideline/ 2022-09-16T09:35:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/fda-and-nih-launch-public-private-partnership-for-rare-neurodegenerative-diseases/ 2022-09-16T09:36:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/valeo-and-the-cea-to-collaborate-on-advanced-research-in-power-electronics-to-prepare-for-tomorrows-electric-mobility/ 2022-09-16T09:39:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/syros-receives-fda-orphan-drug-designation-for-sy-5609-for-the-treatment-of-pancreatic-cancer/ 2022-09-16T09:40:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/rayzebio-propels-forward-with-418-million-raised-since-inception-to-advance-targeted-radiopharmaceuticals-for-cancer/ 2022-09-16T09:41:39+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/novavax-and-serum-institute-of-india-announce-full-product-registration-in-south-africa-of-novavax-covid-19-vaccine-as-a-primary-series-for-adults-aged-18-and-older/ 2022-09-16T09:43:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/novartis-invests-in-early-technical-development-capabilities-for-next-generation-biotherapeutics/ 2022-09-16T09:44:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/novo-nordisk-and-microsoft-collaborate-to-accelerate-drug-discovery-and-development-using-big-data-and-artificial-intelligence/ 2022-09-16T09:45:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/amerisourcebergen-to-expand-global-biopharma-services-platform-with-acquisition-of-pharmalex/ 2022-09-16T09:47:39+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Amerisource.jpg http://www.pharmajournalist.com/fda-approves-sotyktu-deucravacitinib-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis/ 2022-09-16T09:49:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/autobahn-therapeutics-announces-successful-financing-to-support-strategic-advancement-of-abx-002-for-treatment-resistant-depression/ 2022-09-16T09:51:25+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/oncodna-announces-the-operational-launch-of-its-oncodeep-kit-for-comprehensive-genomic-profiling-of-solid-tumors/ 2022-09-16T09:54:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/innocare-announces-approval-of-clinical-trial-of-bcl2-inhibitor-icp-248-in-china/ 2022-09-16T09:57:22+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/Innocare-Logo.png http://www.pharmajournalist.com/nacuity-pharmaceuticals-and-arctic-therapeutics-enter-licensing-agreement-and-strategic-partnership-to-develop-npi-001/ 2022-09-16T09:58:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/strata-oncology-announces-expansion-of-clinical-collaboration-with-pfizer-for-strata-path-trial-into-early-stage-cancer/ 2022-09-16T09:59:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/strata-oncology-logo.jpg http://www.pharmajournalist.com/briacell-partners-with-caris-life-sciences-to-expand-patient-outreach-and-molecular-profiling/ 2022-09-16T10:00:54+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/oxford-biomedica-solutions-signs-agreement-with-new-partner-for-aav-platform/ 2022-09-16T10:02:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/oxford-biomedica.jpg http://www.pharmajournalist.com/avicanna-expands-its-epilepsy-research-program-with-a-new-collaboration-with-the-university-of-toronto/ 2022-09-16T10:03:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/caladrius-biosciences-and-cend-therapeutics-announce-closing-of-merger-and-the-emergence-of-lisata-therapeutics/ 2022-09-16T10:04:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/neurobo-pharmaceuticals-inc-and-dong-a-st-co-ltd-announce-strategic-collaboration-to-license-and-develop-portfolio-of-dong-as-cardio-metabolic-therapies/ 2022-09-16T10:06:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/mallinckrodt-receives-fda-approval-for-terlivaz-terlipressin-for-injection-for-the-treatment-of-hepatorenal-syndrome-hrs/ 2022-09-16T10:07:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/mallinckrodt-pharma.jpg http://www.pharmajournalist.com/novome-biotechnologies-raises-43-5-million-series-b-financing-to-advance-its-pipeline-of-therapeutically-engineered-microbes/ 2022-09-16T10:08:52+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/meet-pfizer-astrazeneca-dime-many-more-at-the-biosensors-for-medical-wearables-conference/ 2022-09-16T11:15:53+00:00 https://pharmajournalist.com/wp-content/uploads/2022/09/TP-002-2022-650x650-1.jpg https://pharmajournalist.com/wp-content/uploads/2022/09/TP-002-2022-650x650-1.jpg http://www.pharmajournalist.com/in-4-weeks-meet-pfizer-astrazeneca-dime-many-more-at-the-biosensors-for-medical-wearables-conference/ 2022-09-22T16:58:53+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/Medical-Wearables-for-Biosensors-USA.jpg http://www.pharmajournalist.com/pfizer-to-supply-global-fund-up-to-6-million-paxlovid-treatment-courses-for-low-and-middle-income-countries/ 2022-09-23T09:33:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/gsk-and-spero-therapeutics-announce-exclusive-licence-agreement-for-tebipenem-hbr/ 2022-09-23T09:35:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/sesen-bio-and-carisma-therapeutics-announce-merger-agreement/ 2022-09-23T09:36:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/abpro-finalizes-strategic-partnership-with-celltrion-for-worldwide-development-and-commercialization-of-a-cancer-treatment-bispecific-antibody/ 2022-09-23T09:37:39+00:00 https://pharmajournalist.com/wp-content/uploads/2019/03/abpro-therapeutics-logo.png http://www.pharmajournalist.com/avrobio-receives-rare-pediatric-disease-designation-from-u-s-food-and-drug-administration-fda-for-first-gene-therapy-in-development-for-cystinosis/ 2022-09-23T09:39:22+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/AVROBIO-Logo.png http://www.pharmajournalist.com/cytoreason-announces-expanded-collaboration-deal-with-pfizer-to-deliver-ai-for-drug-discovery-and-development/ 2022-09-23T09:40:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/rocket-pharmaceuticals-to-acquire-renovacor-extending-leadership-in-aav-based-cardiac-gene-therapy/ 2022-09-23T09:41:48+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/rocket-pharmaceuticals-logo.jpg http://www.pharmajournalist.com/european-commission-approves-roches-vabysmo-the-first-bispecific-antibody-for-the-eye-for-two-leading-causes-of-vision-loss/ 2022-09-23T09:43:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/genfit-to-acquire-clinical-stage-biopharmaceutical-company-versantis-expanding-its-portfolio-in-liver-diseases/ 2022-09-23T09:49:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/nice-recommends-beigenes-brukinsa-zanubrutinib-for-patients-with-waldenstroms-macroglobulinemia-who-have-had-at-least-one-treatment/ 2022-09-23T09:55:19+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/bristol-myers-squibb-receives-european-commission-approval-for-lag-3-blocking-antibody-combination-opdualag-nivolumab-and-relatlimab-for-the-treatment-of-unresectable-or-metastatic-melanoma-with-t/ 2022-09-23T09:56:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/bluebird-bio-receives-fda-accelerated-approval-for-skysona-gene-therapy-for-early-active-cerebral-adrenoleukodystrophy-cald/ 2022-09-23T09:58:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/bluebird-bio-inc.jpg http://www.pharmajournalist.com/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-treatment-of-covid-19/ 2022-09-23T09:59:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/aptar-expands-pharmaceutical-services-announces-exclusive-collaboration-between-aptar-pharma-and-fluidda/ 2022-09-23T10:26:59+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Aptar-Pharma-Logo.jpg http://www.pharmajournalist.com/clearmind-applies-for-patent-to-treat-obesity-and-metabolic-syndrome/ 2022-09-23T10:30:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/coeptis-therapeutics-enters-exclusive-license-agreement-with-university-of-pittsburgh-for-rights-to-snap-car-a-multi-antigen-car-t-technology/ 2022-09-23T10:32:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/gilead-sciences-completes-acquisition-of-mirobio/ 2022-09-23T10:33:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gilead.jpg http://www.pharmajournalist.com/veranex-expands-european-medtech-capabilities-with-acquisition-of-medidee/ 2022-09-23T10:36:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/repligen-expands-process-analytics-portfolio-with-drs-daylight-solutions-agreement/ 2022-09-23T10:37:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/advanced-nanotherapies-sirplux-duo-drug-coated-balloon-receives-fda-breakthrough-designation-for-small-vessel-coronary-artery-disease/ 2022-09-23T10:38:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg